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bstract
The contribution of occupational exposures to rare cancers, which represent 22% of all cancers diagnosed annually in Europe, remains
nsufficiently considered. We conducted a comprehensive review of occupational risk factors in 67 rare cancers (annual incidence <6/100,000).
n examination of relevant articles in PubMed (1960–2012) and the International Agency for Research on Cancer (IARC) monographs revealed
hat 26 cancer sites, such as mesothelioma, nasal, larynx, liver, ovarian cancer, bone sarcoma, and hematopoietic malignancies were consistently
inked to occupational factors. Main exposures included asbestos, wood dust, metals/metalloids, formaldehyde, benzene, vinyl chloride, and
adiation. There was inconsistent evidence regarding 22 rare malignancies. We did not identify relevant data for 19 rare cancers. Despite
imitations of published evidence, our review provides useful information that can facilitate the identification of work-related factors that
ontribute to rare cancers. International collaborations, development of improved exposure assessment methods, and molecular approaches
an improve future studies.
 2014 The Authors. Published by Elsevier Ireland Ltd. 
eywords: Rare cancer; Occupational; Exposure; Epidemiology; IARC; Classifica
Open access under CC BY-NC-SA license. tion
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.  Introduction
Despite their low occurrence, more than 500,000 rare can-
ers are diagnosed each year in Europe, corresponding to
2% of all cancers annually and one quarter of the total can-
er prevalence [1]. Several rare malignancies are now well
nown to be caused by occupational factors, such as pleural
esothelioma in asbestos workers [2,3], nasopharyngeal car-
inoma in wood workers [4] or liver angiosarcoma in vinyl
hloride workers [5]. However, occupational exposures in
any rare cancers remain under-reported due to lack of evi-
ence and/or awareness by clinicians. Therefore, our article
imed to review the available evidence from epidemiology
tudies and IARC monographs to provide a synthesis of estab-
ished and suspected occupational exposures associated with
are cancers.
.  Methods
We only considered here rare cancers, i.e., those with
n incidence of <6 per 100,000 cases per year, accord-
ng to RARECARE [1]. We searched PubMed from 1960
o December 2012, using search terms related to occu-
ational exposure and specific cancer sites (Table 1). We
ncluded articles in English, French, German or Spanish.
verall, we identified 6820 articles. Possibly relevant arti-
les were selected through assessment of titles and abstracts
nd through the reference lists of related articles. We further
earched the International Agency for Research on Can-
er (IARC) monographs (http://monographs.iarc.fr/). Studies
ere selected according to the following criteria: study
esign (cohort or case–control study); original study or
eta-analyses; studies providing histology to differentiate
etween subtypes; studies providing information on asso-
iation between cancer risk (effect size) and occupational
xposure (i.e., included odds ratio [OR], relative risk [RR],
tandardized incidence ratio [SIR], or mortality rate ratio
SMR]). We selected in priority studies with detailed occupa-
ional exposure assessment, rather than studies based solely
n job titles. When available, we preferentially selected meta-
nalyses. Only associations supported by consistent evidence
rom several studies were recorded (Tables 2 and 3). Also,
hen an association was consistently supported by numerous
tudies, the most recent data were retained. Finally, 187 arti-
les and relevant data from IARC monographs were included
Tables 2 and 3).
.  Results
We included 67 rare cancers in our review. For 26 can-
ers (marked with an asterisk (*)), an association with
ccupational exposure was supported by IARC mono-
raphs and/or consistent evidence from epidemiology studies
Tables 2 and 3). We distinguished for each cancer site,
t
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ccupational exposures classified by IARC with “sufﬁcient
vidence” for carcinogenicity (i.e. a causal relationship has
een established between exposure to the agent and the given
ancer type) or “limited  evidence”  for carcinogenicity (i.e. a
ositive association for which a causal interpretation is con-
idered to be credible, but chance, bias or confounding could
ot be ruled out with reasonable confidence) [6] as well as
ccupational exposures supported by consistent epidemiol-
gy evidence. For 22 rare malignancies (marked with two
sterisks (**)), there was inconsistent or insufficient evidence
Table 3). Finally, we did not identify relevant occupational
xposure studies for 19 cancers (Table 3). Some histology
ubtypes or rare cancers are covered by the IARC classifica-
ion for a larger cancer entity. This is specified in the text and
ables (Tables 2 and 3). Unless otherwise stated for a cancer
ite, no IARC classification exists.
.1.  Head  and  neck  cancers
.1.1.  Epithelial  tumors  of  the  nasal  cavity  and  sinuses*
IARC has classified several occupational exposures as
arcinogens for nasal cavity and sinuses with sufficient evi-
ence (isopropyl alcohol production, leather dust, nickel
ompounds, radium, wood dust) or limited evidence (carpen-
ry and joinery, chromium (VI) compounds, formaldehyde,
extile manufacturing). Epidemiological studies have con-
istently associated cancer of the nasal cavity with wood
ust, leather dust, nickel and radium [4,7–10]. Epidemi-
logical evidence remains insufficient for other agents
ncluding chromium, arsenic, formaldehyde and welding
umes [7,11–13]. Adenocarcinomas has been associated with
ood dust, leather dust, and formaldehyde [7,13], whereas
quamous cell carcinomas has been recently linked to arsenic
nd welding fumes [7].
.1.2. Epithelial  tumors  of  the  nasopharynx*
IARC has classified wood dust and formaldehyde as car-
inogenic for nasopharynx with sufficient evidence [14–17].
lso, nasopharyngeal carcinoma has been associated with
hlorophenol exposure, mainly for machinists [18], as well
s industrial heat [17].
.1.3. Epithelial  tumors  of  the  major  salivary  glands**
Although few studies have focused on salivary gland
ancer, occupational exposure to either ionizing radiation
r formaldehyde have been linked to this cancer type
19].
.1.4.  Epithelial  tumors  of  the  hypopharynx*
Few studies have considered the hypopharynx separately
rom pharyngeal cancer. IARC has classified asbestos expo-wofold increase in hypopharyngeal cancer risk was identi-
ed for asbestos exposure [20]. Increased risk has also been
eported for exposure to iron and steel [21].
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Table 1
Search strategy and number of paper identified by cancer site.
Cancer type Search strategy Number of
references
identified
Search terms related to occupational exposure:
((occupation[Tiab] OR occupational[Tiab] OR work[Tiab] OR worker*[Tiab]) AND (exposure[Tiab] OR exposures[Tiab] OR exposed[Tiab]) AND
(English[lang] OR French[lang] OR German[lang] OR Spanish[lang])).
Search terms related to speciﬁc cancer sites:
Adapted from the National Cancer Institute: http://www.cancer.gov/cancertopics/litsearch
Head and neck cancers
Cancer of the nasal cavity and
sinuses
(nose neoplasm*[Tiab] OR ((nose[Tiab] OR nasal[Tiab] OR sinonasal[Tiab] OR
paranasal[Tiab] OR sinus[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])))
403
Naso-pharyngeal cancer (NPC) (nasopharynx[Tiab] OR nasopharyngeal[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab]
OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])
87
Cancers of the salivary gland (salivary gland neoplasm*[Tiab]) OR ((salivary[Tiab] OR parotid[Tiab] OR sublingual[Tiab]
OR submandibular[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignant[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])))
30
Hypo-pharyngeal cancer (hypopharyngeal neoplasms[Tiab]) OR ((hypopharyn*[Tiab] AND (cancer*[Tiab] OR
carcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]))
17
Laryngeal cancer (laryngeal neoplasms[Tiab] OR ((laryngeal[Tiab] OR larynx[Tiab] OR glottis[Tiab] OR
glottic[Tiab] OR subglottis[Tiab] OR subglottic[Tiab] OR supraglottis[Tiab] OR
supraglottic[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab]
OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])))
276
Pharyngeal cancer pharyngeal neoplasms[Tiab]) OR ((pharyn*[Tiab] AND (cancer*[Tiab] OR carcinoma*[Tiab]
OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
118
Oropharyngeal cancer oropharyngeal neoplasms[Tiab]) OR ((oropharyn*[Tiab] AND (cancer*[Tiab] OR
carcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]))
25
Cancer of the oral cavity (oral[Tiab] OR mouth[Tiab] OR lip[Tiab] OR gingiva[Tiab] OR gingival[Tiab] OR
tongue[Tiab] OR palate[Tiab] OR palatal[Tiab] OR buccal[Tiab]) AND (cancer*[Tiab] OR
carcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])
405
Cancer of the lip
Gastrointestinal cancers
Squamous cell carcinoma of the
esophagus
(squamous cell[Tiab] AND (oesophag*[Tiab] OR esophagi*[Tiab])) AND (cancer*[Tiab] OR
carcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]))
8
Adenocarcinoma of the esophagus (adenocarcinoma*[Tiab] AND (esophag*[Tiab] OR oesophag*[Tiab])) AND (cancer*[Tiab]
OR carcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]))
15
Carcinoma of the small intestine ((duodenal neoplasm*[Tiab] OR ileal neoplasm*[Tiab] OR jejunal neoplasm*[Tiab])) OR
(((small[Tiab] AND (intestine*[Tiab] OR intestinal[Tiab] OR bowel*[Tiab])) OR
(duodenal[Tiab] OR duodenum[Tiab] OR ileal[Tiab] OR ileum[Tiab] OR jejunal[Tiab] OR
jejunum[Tiab])) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab] OR
malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])))
51
Cancer of the anal canal ((anus neoplasms[Tiab]) OR ((anal[Tiab] OR anus[Tiab] OR perianal[Tiab]) AND
(cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR
tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
7
Hepatocellular carcinoma of the
liver and intrahepatic bile tract
(IBT)
((liver neoplasm*[Tiab] OR cholangiocarcinoma[Tiab] OR hepatocellular carcinoma*[Tiab]
OR hepatoblastoma*[Tiab] OR hepatoma*[Tiab]) OR ((liver*[Tiab] OR intrahepatic[Tiab]
OR hepatic[Tiab] OR hepatocellular[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])))
853
Angiosarcoma ((liver[Tiab] OR hepatic[Tiab]) AND angiosarcoma[Tiab]) 107
Epithelial tumors of gallbladder
and extrahepatic biliary tract
(EBT)
gallbladder[Tiab] OR extrahepatic[Tiab] 36
Thoracic cancers
Epithelial tumor of the trachea ((trachea[Tiab]) OR tracheal[Tiab])) AND (((cancer*[Tiab]) OR tumor*[Tiab]) OR
tumor*[Tiab])
41
Large cell lung carcinoma (((large[Tiab]) AND cell[Tiab]) AND lung[Tiab]) AND ((carcinoma*[Tiab]) OR
cancer*[Tiab])
60
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Table 1 (Continued )
Cancer type Search strategy Number of
references
identified
Bronchiolo-alveolar lung
carcinoma
((bronchiolo-alveolar[Tiab]) AND lung[Tiab]) AND (carcinoma*[Tiab] OR cancer*[Tiab]) 2
Epithelial tumors of the thymus AND (thymoma[Tiab] OR (thymus[Tiab] AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])))
34
Mesothelioma (mesothelioma*[Tiab]) 1007
Reproductive cancers
Mammary Paget’s Disease ((mammary[Tiab]) AND paget’s[Tiab]) AND disease[Tiab]) 0
Epithelial tumors of the male
breast
(male[Tiab] AND (breast neoplasms[Tiab] OR dcis[Tiab] OR lcis[Tiab] OR ((breast*[Tiab]
OR mammary[Tiab] OR nipple*[Tiab]) AND ((cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]) OR in situ[Tiab])))
95
Epithelial tumors of the cervix
uteri
(cervix neoplasms[Tiab]) OR((cervix[Tiab] OR cervical[Tiab] OR exocervix[Tiab] OR
exocervical[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab]
OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
144
Ovarian cancer (ovarian neoplasm*[Tiab]) OR ((ovarian[Tiab] OR ovary[Tiab] OR ovaries[Tiab]) AND
(cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR
tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
170
Carcinoma of the vulva and vagina (((vaginal neoplasm*[Tiab] OR vulvar neoplasm*[Tiab]) OR ((vagina [Tiab] OR vulva[Tiab]
OR (bartholin[Tiab] AND gland[Tiab])) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])))
8
Urogenital cancers
Testicular cancer (testicular neoplasms[majr] AND human[mh] AND english[la]) OR ((testicular[Tiab] OR
testis[Tiab] OR testicle*[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])
152
Extragonadal germ cell tumors (neoplasms, germ cell and embryonal[MeSH Terms] OR (germcell[Tiab] OR germ cell[Tiab]
OR dysgerminoma[Tiab] OR extragonadal[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab]
OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]))
296
Penis carcinoma (penile neoplasms[majr] AND human[mh]) [la]) OR ((penile[Tiab] OR penis[Tiab]) AND
(cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR
tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
5
Squamous cell carcinoma of the
kidney
squamous[Tiab] AND cell[Tiab] AND kidney AND (adenocarcinoma*[Tiab] OR
carcinoma*[Tiab])
10
Non-transitional cell carcinoma of
the urinary bladder
((bladder neoplasms[majr] OR (bladder[Tiab] AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab])) AND (non-transitional[Tiab] OR squamous[Tiab] OR
adenocarcinoma*[Tiab] OR sub-type[Tiab] OR histolog*[Tiab]))
54
Non-bladder urinary organs (renal
pelvis, ureter, urethra)
((urologic neoplasms[majr] AND Carcinoma, Transitional Cell[majr]]) OR ((urologic[Tiab]
OR urinary[Tiab] OR urothelial[Tiab] OR urethra*[Tiab] OR paraurethra*[Tiab] OR
ureter[Tiab] OR (renal[Tiab] AND pelvis[Tiab])) AND (cancer*[Tiab] OR carcinoma*[Tiab]
OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab]) AND (TCC[Tiab] OR (transitional[Tiab] AND cell[Tiab]))))
76
Neuroectodermic and mesodermic tumors
Malignant melanoma of mucosa (melanoma[Tiab]) AND mucosa[Tiab]) 2
Epithelial tumors of the eye and
adnexa
(((cancer*[Tiab]) OR tumor*[Tiab]) OR tumor*[Tiab]) AND ((eye[Tiab]) OR adnexa[Tiab]) 81
Malignant melanoma of the uvea (melanoma*[Tiab] AND eye[Tiab]) 29
Soft-tissue sarcoma (soft-tissue sarcoma*[Tiab]) 90
Bone sarcoma (bone[Tiab]) AND sarcoma*[Tiab] 27
Glial tumors of the central nervous
system
Glioma*[Tiab] OR (glial*[Tiab] AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab]))
113
Malignant meningioma Meningioma*[Tiab] AND (cancer*[Tiab] OR carcinoma*[Tiab] OR malignan*[Tiab] OR
tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab])
26
Neuroendocrine tumors Neuroendocrine[Tiab]) AND ((cancer*[Tiab] OR carcinoma*[Tiab] OR malignant OR
malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab]))
9
Endocrine tumors
Carcinoma of the pituitary gland ((pituitary neoplasms[Tiab] OR (pituitary[Tiab] AND (tumor*[Tiab] OR tumor*[Tiab] OR
neoplasm*[Tiab] OR malignan*[Tiab]))
34
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Table 1 (Continued )
Cancer type Search strategy Number of
references
identified
Carcinoma of the thyroid gland thyroid neoplasm*[Tiab] OR (thyroid[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR
malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab])
196
Carcinoma of the parathyroid
gland
((parathyroid neoplasms[Tiab] OR parathyroid AND (cancer*[Tiab] OR carcinoma*[Tiab]
OR adenocarcinoma*[Tiab] OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab]))
10
Carcinoma of the adrenal gland adrenal cortical carcinoma[Tiab] OR ((adrenocortical[Tiab] OR adrenal[Tiab]) AND
(cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab]))
28
Lymphoid diseases
Hodgkin disease ((hodgkin disease[majr] AND human[mh]) OR (((hodgkin[Tiab] OR hodgkins[Tiab]) NOT
(non-hodgkin[ti] OR non-hodgkins[ti])) AND (lymphoma[Tiab] OR lymphomas[Tiab] OR
disease[Tiab])))
35
Acute lymphoblastic leukemia ((lymphoblastic leukemia, acute[majr] AND human[mh]) OR (acute lymphoblastic
leukemia[tiab] OR acute lymphocytic leukemia[tiab]))
63
Burkitt lymphoma ((b-cell lymphoma[majr] AND human[mh]) OR (Burkitt[Tiab] AND (lymphoma[Tiab] OR
lymphomas[Tiab])))
22
Cutaneus T cell
lymphoma/mycosis fungoides
((cutaneous t-cell lymphoma[majr] AND human[mh]]) OR CTCL[Tiab] OR (mycosis[Tiab]
AND fungoides[ti]) OR ((cutaneous[Tiab] OR skin[Tiab]) AND t-cell[Tiab] AND
(lymphoma[Tiab] OR lymphomas[Tiab])))
22
Other T cell lymphoma and NK
cell neoplasms
((t-cell lymphoma[majr] AND human[mh]) OR ((t-cell[Tiab] OR (t[Tiab] AND
lymphoblastic[Tiab]) OR NK-cell[Tiab] OR anaplastic large cell[Tiab] OR
angioimmunoblastic[Tiab] OR sezary syndrome[Tiab] OR angiocentric[ti]) AND
(lymphoma[Tiab] OR lymphomas[Tiab])))
53
Diffuse large B-cell lymphoma
(DLBCL)
((b-cell lymphoma[majr] AND human[mh]) OR ((b-cell[Tiab] OR large-cell[Tiab] OR
diffuse well-differentiated lymphocytic[Tiab] OR large-b-cell [Tiab]) AND (lymphoma[Tiab]
OR lymphomas[Tiab])))
58
Follicular B lymphoma (FL) ((b-cell lymphoma[majr] AND human[mh]) OR (follicular[Tiab] AND (lymphoma[Tiab] OR
lymphomas[Tiab])))
37
Hair cell leukemia ((hairy cell leukemia[majr] AND human[mh]]) OR (hairy[Tiab] AND cell[Tiab] AND
(leukemia[Tiab] OR leukemias[Tiab] OR leukemia[Tiab] OR leukaemias[Tiab])) OR
((leukemic[Tiab] OR leukaemic[Tiab]))
87
Multiple myeloma (MM) ((plasmacytoma[majr] AND human[mh]) OR MGUS[Tiab] OR plasmacytoma[Tiab] OR
plasmacytomas[Tiab] OR multiple myeloma[Tiab] OR multiple myelomas[Tiab] OR plasma
cell neoplasm[Tiab] OR plasma cell neoplasms[Tiab])
205
Other non-Hodgkin, mature B cell lymphoma
Chronic lymphocytic leukemia
(CLL)/small lymphocytic
lymphoma (SLL)
((lymphocytic leukemia, chronic[majr] AND human[mh]) OR CLL[Tiab] OR mu heavy chain
disease[Tiab] OR mu-chain disease[Tiab] OR ((chronic[Tiab] OR b-cell[Tiab]) AND
(lymphocytic[Tiab] OR lymphoid[Tiab] OR lymphogenous[Tiab] OR aleukemic[Tiab] OR
aleukaemic[Tiab]) AND ((leukemia[Tiab] OR leukemias[Tiab] OR leukemia[Tiab] OR
leukaemias[Tiab]) OR disorders[Tiab])))
136
Marginal zone lymphoma/MALT
lymphoma
((b-cell lymphoma[majr] AND human[mh]) OR ((MALT[Tiab] OR marginal zone[Tiab])
AND (lymphoma[Tiab] OR lymphomas[Tiab])))
18
Mantle cell lymphoma ((b-cell lymphoma[majr] AND human[mh]) OR (mantle cell[Tiab] AND (lymphoma[Tiab]
OR lymphomas[Tiab])))
17
Lymphoplasma-citic
lymphoma/macroglobulinemia
Waldestrom
((b-cell lymphoma[majr] AND human[mh]) OR ((lymphoplasmacytic[Tiab] OR
waldenstrom[Tiab] OR macroglobulinemia[Tiab]) AND (lymphoma[Tiab] OR
lymphomas[Tiab])))
21
Acute myeloid leukemia ((myeloid leukemia, acute[majr] AND human[mh]) OR (AML[ti] OR acute myeloid
leukemia[ti] OR acute myelogenous leukemia[ti] OR acute myeloblastic leukemia[ti]))
167
Chronic myeloid leukemia ((myelogenous leukemia, chronic[majr] AND human[mh]) OR (CML[Tiab] OR
(chronic[Tiab] AND (myeloid[Tiab] OR myelogenous[Tiab] OR granulocytic[Tiab]) AND
(leukemia[Tiab] OR leukemias[Tiab] OR leukemia[Tiab] OR leukaemias[Tiab] OR
disorders[Tiab]))))
90
Other myelodysplastic and
myeloproliferative neoplasms
(“myelodysplastic myeloproliferative diseases”[MeSH Major Topic] AND human[mh]) OR
((myelodysplastic [Tiab] OR myeloproliferative [Tiab]) AND (leukemia[Tiab] OR
leukemias[Tiab] OR leukemia[Tiab] OR leukaemias[Tiab] OR disorders[Tiab]))
46
Histiocytic and dendritic cell
neoplasms
(histiocytic[Tiab] OR dendritic[Tiab]) AND (neoplasm[Tiab] OR neoplasms[Tiab] OR
sarcoma[Tiab] OR sarcomas[Tiab] OR lymphoma[Tiab] OR lymphomas[Tiab])
6
Childhood cancer parental[Tiab] OR maternal[Tiab] OR paternal[Tiab] OR childhood[Tiab] OR offspring[Tiab]
OR prenatal[Tiab]) AND (cancer*[Tiab] OR carcinoma*[Tiab] OR adenocarcinoma*[Tiab]
OR malignan*[Tiab] OR tumor*[Tiab] OR tumor*[Tiab] OR neoplasm*[Tiab] OR
leukemia[Tiab] OR lymphoma[Tiab])
500
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Table 2
Associations supported by consistent evidence and relevant IARC classifications by cancer site.
Cancer type Occupational
exposure
Risk level (95% confidence intervals) IARC Classification
Head and neck cancers
Cancer of the nasal
cavity and sinuses
Wood dust d’Errico et al. [7]: Hospital based case control
study (113 cases, 336 controls)
OR for adenocarcinoma: 58.6 (23.74–144.8),
adjusted for age and sex
Demers et al. [4]: data from 12 case control studies
(680 male cases, 2349 male controls, 250 female
cases, and 787 female controls)
Adenocarcinoma among men: OR = 3.1 (1.6–6.1)
for moderate exposure and 45.5 (28.3–72.9) for high
wood dust, adjusted for study and age
Little evidence for squamous cell carcinoma
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 C, 2012)
Nickel Grimsrud et al. [8]: Cohort study among workers
employed at a nickel refinery (2 cases, 0.23
expected)
SMR = 870 (105–3141)
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 C, 2012)
Leather dust d’Errico et al. [7]: Hospital based case control
study (113 cases, 336 controls)
OR for adenocarcinoma: 26.6 (5.09–139.0) age and
sex adjusted and 32.8 (5.96–181.1) when including
wood dust exposure in the model
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 C, 2012)
Formaldehyde d’Errico et al. [7]: Hospital based case control
study (113 cases, 336 controls)
OR for adenocarcinoma 9.5 (2.62–34.20) age and
sex adjusted
Luce et al. [13]: Pooled analysis of 12 studies (930
cases 3136 controls) from seven countries
OR for adenocarcinoma in men: 3.0 (1.5–5.7) in the
high level of exposure category, adjusted for age,
exposure to wood dust and leather dust
OR for adenocarcinoma in women 6.2 (2.0–19.7) in
the high level of exposure category, adjusted for age
Group 1.
Limited evidence for this specific
site.
(Vol. 100 F, 2012)
Chromium Rosenman et al. [11]: Cohort study among 3408
workers from facilities producing chromium
compounds. 6 cases of sino-nasal cancers were
observed.
PMR = 6.85 (3.14–14.94) in white men. No
adjustment.
Hernberg et al. [12]: Case control study (167 cases
and 167 controls) from Denmark, Finland or
Sweden.
OR = 2.7 (1.1–2.6). No adjustment.
Group 1.
Limited evidence for this specific
site.
(Vol. 100 C, 2012)
Arsenic d’Errico et al. [7]: Hospital based case control
study (113 cases, 336 controls)
OR for squamous cell carcinoma: 5.2 (1.20–22.20)
age and sex adjusted
Group 1.
No evidence for this specific site.
(Vol. 100 C, 2012)
Welding fumes d’Errico et al. [7]:
OR for squamous cell carcinoma: 4.1 (1.66–10.13)
age and sex adjusted
Group 2B.
(Vol. 49, 1990)
Nasopharyngeal
cancer (NPC)
Formaldehyde Bachand et al. [14]: Meta-analysis on case control
studies
Overall OR = 1.22 (1.00–1.50), based on 6 case
control studies
Overall OR adjusted for smoking = 1.10 (0.8–1.51)
based on 6 case control studies
Bosetti et al. [15]: Meta-analysis on 12 cohort
studies
Meta-SMR = 1.33 (0.61–2.53)
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 F, 2012)
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Table 2 (Continued )
Cancer type Occupational
exposure
Risk level (95% confidence intervals) IARC Classification
Wood dust Hildesheim et al. [16]:
OR for wood dust any level: 1.7 (1.0–3.0) adjusted
for age, sex, education, and ethnicity
>10 years OR = 2.4 (1.1–5.0); p for trend: 0.02;
adjusted for age, sex, education, ethnicity
Armstrong et al. [17]: case control study 282 cases
with squamous cell nasopharyngeal carcinoma, 282
controls
OR = 2.36 (1.33–4.19) adjusted for diet and cigarette
smoke
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 C, 2012)
Chlorophenol Mirabelli et al. [18]: 92 nasopharyngeal carcinoma
cases from cancer registries and 1909 controls
obtained through random digit dialing
OR = 1.94 (1.03–3.50) among those with medium or
high intensity chlorophenol exposure, adjusted for
registry, age group, Asian ethnicity, and smoking
status
Group 2B.
(Vol. 71, 1999)
Industrial heat Armstrong et al. [17]:
OR = 2.21 (1.12–4.33) adjusted for diet and cigarette
smoke
No IARC classification for this
exposure.
Cancer of the salivary
gland
Ionizing radiations Wilson et al. [19]: Death certificate-based case
control study on salivary gland cancer. African
American (168 cases, 672 controls) and white (2237
cases, 8748 controls) cases from 24 states
(1984–1989) matched to controls by age, sex, race,
and region. Job exposure matrix
OR = 1.7 (1.05–2.80) in white men exposed to
mid-high probability and intensity adjusted for age,
marital and social status
Group 1.
Sufficient evidence for this specific
site but not from occupational
exposure contexts.
(Vol. 100 D, 2012)
Formaldehyde Wilson et al. [19]:
OR = 1.6 (1.30–2.00) in white men exposed to
mid-high probability and intensity adjusted for age,
marital and social status
Group 1.
No evidence for this specific site.
(Vol. 100 F, 2012)
Hypo-pharyngeal
cancer
Asbestos Marchand et al. [20]: Hospital-based case control
(206 hypopharyngeal cancer cases/305 controls with
other types of cancer
Ever exposed OR = 1.80 (1.08–2.99) adjusted for
age, smoking, and alcohol consumption
Highest level of exposure OR = 2.14 (1.14–4.01)
adjusted for age, smoking, and alcohol consumption
Group 1.
Limited evidence for pharynx.
(Vol. 100 C, 2012)
Mild steel dust Shangina et al. [21]: Hospital controls based case
control study (350 cases/34 hypopharyngeal cancer
and 728)
OR = 3.04 (1.39–6.64) adjusted for age, country,
tobacco smoking, and alcohol consumption
Dose–response relationship with cumulative
exposure (p for trend 0.006)
Iron and steel founding (occupational
exposure during) classified Group 1.
No evidence for this site.
(Vol. 100 F, 2012)
Iron compounds
and fumes
Shangina et al. [21]:
OR = 2.74 (1.29–5.84) adjusted for age, country,
tobacco smoking, and alcohol consumption
Dose-response relationship with exposure duration
(p for trend 0.03)
Laryngeal cancer Asbestos Goodman et al. [24]: Meta-analysis based on 69
asbestos-exposed occupational cohorts
Meta-SMR = 133 (114–155)
IOM [25]: Meta-analysis of 15 cohort studies
Any exposure overall relative risk: 1.4 (1.19–1.64)
High exposure overall relative risk: 2.02 (1.64–2.47)
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 C, 2012)
B. Charbotel et al. / Critical Reviews in Oncology/Hematology 90 (2014) 99–134 107
Table 2 (Continued )
Cancer type Occupational
exposure
Risk level (95% confidence intervals) IARC Classification
Acid mists Steenland [23]: Cohort of 1156 male steelworkers
SIR = 2.2 (1.2–3.7) adjusted on tobacco smoking
Group 1.
Sufficient evidence for this specific
site.
(Vol. 100 F, 2012)
Silica dust Chen et al. [26]: Meta-analysis
Case control studies (n = 6): pooled OR = 1.39
(1.17–1.67) adjustment for smoking and alcohol
consumption
Cohort studies silicosis cases (n = 5): pooled
SMR = 1.38 (0.79–1.96)
Silica dust exposed worker: pooled SMR = 1.13
(0.82–1.45) based on six studies
Pooled SIR = 1.50 (0.59–2.42) based on three studies
Group 1.
No evidence for this specific site.
(Vol. 100 C, 2012)
Engine exhaust Paget-Bally et al. [27]: Meta-analysis for agents
with at least 10 available studies with homogenous
exposure. 99 publications analyzed
Meta-RR = 1.17 (1.05–1.30)
Engine exhaust, diesel Group 1.
No evidence for this specific site.
(Vol. 105, in prep, meeting in 2012)
Polycyclic
aromatic
hydrocarbons
(PAH)
Paget-Bally et al. [27]: Meta-analysis for agents
with at least 10 available studies with homogenous
exposure. 99 publications analyzed
Meta-RR = 1.29 (1.10–1.52)
Some PAH-related exposures are
Group 1 but none of them for this site
of cancer.
(Vol. 100 F, 2012)
Chlorinated
solvents
Shangina et al. [21]: Hospital based case control
study (350 cases/316 laryngeal cancer cases and 728
controls)
OR = 2.18 (1.03–4.61) adjusted for age, country,
tobacco smoking, and alcohol consumption
No classification for this site.
Passive smoking
at work
Lee et al. [28]: Case control study 542 cases and
2197 controls who reported never using tobacco
Duration of exposure > 15 years OR = 2.07
(1.04–4.11) adjusted for centers, age, sex,
race/ethnicity, education, and alcohol drinking
Duration of exposure >15 years, never alcohol users
OR = 5.45 (1.69–17.52)
Second-hand smoke Group 1.
Limited evidence for this site.
(Vol. 100 E, 2012)
Ionizing radiation Dupree et al. [29]: Retrospective cohort mortality
study of 995 white males employed at a uranium
processing facility (5 larynx cancer cases)
SMR = 447 (144–1043) no adjustment
Group 1.
No evidence for this specific site.
(Vol. 100 D, 2012)
Textile dust Paget Bally et al. [27]: Meta-analysis for agents
with at least 10 available studies with homogenous
exposure (99 publications analyzed)
Meta-RR = 1.41 (1.09–1.83)
Textile manufacturing industry (work
in) is Group 2B. (Vol. 48, 1990)
Electromagnetic
field
low-frequency
(ELF)
Floderus et al. [30]: Swedish cohort study on
1,596,959 men and 806,278 women
In men exposed to medium level (0.084–0.115 T)
RR = 1.5 (1.2–1.9) adjusted for age
In men exposed to high level (≥0.116 T) RR = 1.6
(1.3–2.0) adjusted for age
Group 2B.
(Vol. 80, 2002)
Sulfur mustard Easton et al. [31]: Cohort of 2498 men and 1032
women employed in a manufacture of mustard gas
SMR = 273, p < 0.001 (no adjustment)
Group 1.
Limited evidence for this site.
(Vol. 100 F, 2012)
Pharyngeal cancer Welding fumes Gustavsson et al. [32]: Community based case
referent study (545 cases and 641 referents)
More than 8 years of exposure: OR = 2.3 (1.1–4.7)
accounting for age, region, alcohol consumption and
tobacco smoking
Welding fumes classified group 2B.
No classification for this site.
(Vol. 49, 1990)
Sulfur mustard Easton et al. [31]: Cohort of 2498 men and 1032
women employed in a manufacture of mustard gas
SMR = 549, p < 0.001 (no adjustment)
Group 1.
No evidence for this site.
(Vol. 100 F, 2012)
Cancer of the oral
cavity
Wood dust Smailyte et al. [33]: cohort of woodworkers
exposed to softwood dust (1080 men and 438
women)
Oral cavity SIR in males: 2.83 (1.29–5.37)
Group 1. No evidence for this site.
(Vol. 100 C, 2012)
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Cancer of the lip Outdoor work Kenborg et al. [35]: Nationwide, population-based
case control study. 3187 male cases of lip cancer
ascertained from the Danish Cancer Registry. 9361
controls
Outdoor work >10 years, OR = 1.67 (1.38–2.03)
adjusted for social class and place of birth
Solar radiations are Group 1. Limited
evidence for this site.
(Vol. 100 D, 2012)
Gastrointestinal cancers
Squamous cell
carcinoma of the
esophagus
Carbon black Parent et al. [36]: population based, case-control
study (99 esophageal cancers/63 squamous cell
esophageal carcinomas/1066 controls)
Any exposure OR = 3.4 (1.5–7.7) adjusted for age,
respondent status, birthplace, educational level,
alcohol consumption, carotene index, smoking
Substantial exposure OR = 8.9 (1.2–64.3) adjusted
for age, respondent status, birthplace, educational
level, alcohol consumption, carotene index, smoking
Group 2B.
(Vol. 93, 2010)
Sulfuric acid Parent et al. [36]:
Any exposure OR = 2.8 (1.2–6.1) adjusted for age,
respondent status, birthplace, educational level,
alcohol consumption, carotene index, smoking
Group 1. No evidence for this site.
(Vol. 100 F, 2012)
Chrysotile
asbestos
Parent et al. [36]:
Any exposure OR = 2.0 (1.1–3.8) adjusted for age,
respondent status, birthplace, educational level,
alcohol consumption, carotene index, smoking
Group 1. No evidence for this site.
(Vol. 100 C, 2012)
Polycyclic
aromatic
hydrocarbons
Gustavson et al. [32]: Community based case
referent study (545 cases and 641 referents)
Low level OR = 2.01 (1.16–3.48) adjusted for region,
age, alcohol consumption and smoking habits
High level OR = 1.87 (1.11–3.16) adjusted for
region, age, alcohol consumption and smoking
habits
Some compounds are Group 1. No
evidence for this site.
(Vol. 100 F, 2012)
Adeno-carcinoma of
the esophagus
Sulfur compounds Santiban˜ez et al. [37]: Hospital-based case control
study, 147 squamous cell carcinoma and 38
adenocarcinoma of esophagus and 285 frequency
matched controls
High level of exposure (0.025 ppm) OR for
adenocarcinoma = 3.12 (1.00–9.77) adjusted for age,
province, educational level, alcohol drinking and
tobacco smoking
Group 1. No evidence for this site.
(Vol. 100 F, 2012)
Lead Santiban˜ez et al. [37]: High level of exposure High
(.0.237 mmol/l) OR for adenocarcinoma = 5.30
(1.39–20.22) adjusted for age, province, educational
level, alcohol drinking and tobacco smoking
Group 2 B.
(Vol. 23, Sup 7, 1987)
Cancer of the small
intestine
Asbestos Clin et al. [38]: Cohort of 2024 subjects
occupationally exposed to asbestos (3 cases of small
intestine cancer)
SIR = 6.93 (1.39–20.25) among men with an
exposure exceeding 80 fibers/mL × years (no
adjustment)
Group 1. Limited evidence for
colorectum.
(Vol. 100 C, 2012)
Semiautomatic arc
welding
(MIG/MAG)
Kaerlev et al. [39]: European case control study (79
cases, 579 colon cancer controls, and 2070
population controls)
Small bowel adenocarcinoma OR = 5.0 (1.3–19.6)
adjusted for country, year of birth, and sex
Welding fumes classified group 2B.
No classification for this site.
(Vol. 49, 1990)
Organic solvents Kaerlev et al. [40]: European case control study (84
cases and 2070 population controls)
Small bowel carcinoid tumor OR = 2.0 (CI 1.0–4.2)
adjusted for country, year of birth, and sex
No classification for this site.
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Benzidine Brown et al. [41]: Cohort of 997 individuals employed
at a chemical production facility (4 cases of small
intestine cancer)
SIR = 18.4 (2.2–66.4) among workers with highest level
of exposure (no adjustment)
Group 1.
No classification for this site.
(Vol. 100 F, 2012)
Hepatocellular
carcinoma of the
liver and
intrahepatic bile
tract (IBT)
Polychlorinated
biphenyls (PCBs)
Ahrens et al. [45]: Case control study among men in six
European countries (183 case, 1938 controls)
Exposure to Oils with polychlorinated biphenyls
OR = 2.8 (1.3–5.9) for carcinoma of the extrahepatic
biliary tract (adjusted for age, country and gallstones)
Prince et al. [46]: Cohort mortality study among 2572
workers highly exposed to polychlorinated biphenyls
(PCBs) during the manufacture of electrical capacitors
(11 deaths from biliary passage, liver and gall bladder
cancer)
SMR = 2.11 (1.05–3.77) (no adjustment)
Group 1.
Limited evidence for this specific
site.
(Vol. 107, in prep, meeting in 2013)
Vinyl chloride
monomer
Mastrangelo et al. [47]: Case-referent study nested in a
cohort of 1658 VCM workers
Hepatocellular carcinoma OR = 1.71 (1.28–2.44) for
each extra increase of 1000 ppm × years of VCM
cumulative exposure (adjusted for alcohol and viral
hepatitis infection)
Boffetta et al. [48]: Meta-analysis (8 cohort studies).
Two large studies considered liver cancers other than
ASL separately (n = 68):
Meta-SMR = 1.35 (1.04–1.77) (no adjustment)
Group 1. Sufficient evidence for this
site of cancer.
(Vol. 100 F, 2012)
Toluene and
xylene
Porru et al. [49]: Case control study (144 males with a
liver cancer, 283 male controls)
OR = 2.8 (1.0–7.6) for 20 or more years of exposure
adjusted for age, residence, education, HBsAg and
HCVAb positivity and heavy alcohol consumption
Toluene Group 3.
Xylene Group 3.
(Vol. 71, 1999)
Trichloro-ethylene Wartenberg et al. [50]: Review on trichloroethylene
and cancer
Liver cancer average risk: 1.9 (1.0–3.4) based on SIRs
from 3 cohorts
Group 1. Limited evidence for this
cancer site.
(Vol. 106, in prep, meeting in 2012)
Tetrachloro-
ethylene
Lynge et al. [51]: Cohort of 10,600 laundry and
dry-cleaning workers exposed to tetrachloroethylene
and other solvents
Liver cancer among women SIR = 3.4 (1.4–7.0)
Group 2A. No evidence for this site.
(Vol. 106, in prep, meeting in 2012)
Organic solvents Chen et al. [52]: Meta-analysis of mortality among
workers exposed to organic solvents from 55 studies
Liver and biliary passages SMR = 119.7 (104.4–137.2)
Radon in
underground
miners
Darby et al. [53]: Collaborative analysis of 11 cohort
studies
Liver cancer SMR = 1.73 (1.29–2.28), no clear
dose-exposure relation
Tomasek et al. [54]: Cancer mortality in 4320 uranium
miners in West Bohemia. 22 liver cancer cases.
Liver O/E = 1.67 (1.04–2.52)
Group 1. No mention to this specific
site.
(Vol. 100 D, 2012)
Plutonium Sokolnikov et al. [55]:
Cohort of 17,740 nuclear facility workers
ERRs for liver cancer were 2.6 for males and 29 and for
females
Group 1. Sufficient evidence for liver.
(Vol. 100 D, 2012)
Magnetic field
exposure (ELF)
Floderus et al. [30]: Swedish cohort study including
1,596,959 men from national census and job exposure
matrix based on measurements.
Biliary passage and liver
Medium exposure (0.084–0.115 T) RR = 1.2 (1.1–1.4)
age adjusted
High exposure (≥116 T) RR = 1.3 (1.2–1.5) age
adjusted
Group 2B.
(Vol. 80, 2002)
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Hepatic angiosarcoma Vinyl chloride
monomer
Kielhorn et al. [5]: Review and Meta-Analysis (4 main
cohort studies)
The global SMR from European and north American
studies for all liver cancer including angiosarcoma was
5.33 (4.23–6.82) reaching 280.0 among highest
exposure group (no adjustment)
Group 1. Sufficient evidence for this
site of cancer.
(Vol. 100 F, 2012)
Epithelial tumors of
gallbladder and
extrahepatic biliary
tract (EBT)
Radon in
underground
miners
Tomasek et al. [54]: Cancer mortality in 4320 uranium
miners in West Bohemia. 12 EBT cases.
Gallbladder and extrahepatic bile ducts O/E = 2.26
(1.16–3.94)
Group 1. No mention to this specific
site.
(Vol. 100 D, 2012)
Thoracic cancers
Large cell lung
carcinoma
Asbestos de Klerk et al. [57]: Cohort study among workers from
Wittenoom asbestos industry (2400 men and 149
women, 71 lung cancer cases, 8 LCell)
OR = 2.1 (1.0–4.3) (Ioge) cumulative exposure
(fibers.ml.years) adjusted for tobacco smoking
Group 1. Sufficient evidence for lung
cancer.
(Vol. 100 C, 2012)
Diesel exhaust Villeneuve et al. [58]: Case control study among men
≥40 years (1681 incident cases of lung cancer and 2053
population controls)
OR across the three increasing tertiles of cumulative
lifetime exposure: 1.06, 1.19, 1.68 (p = 0.02), adjusted
for age, province, tobacco smoking, occupational
exposure to silica and asbestos
Group 1. Sufficient evidence for lung.
(Vol. 105, in prep, meeting in 2012)
Mesothelioma Asbestos Harding et al. [59]: Cohort of 98,912 asbestos workers
(649 mesothelioma cases)
SMR men: 13.3 (12.3–14.4)
SMR women: 30.9 (18.3–48.8)
Loomis et al. [60]: Cohort of 5770 asbestos textile
workers (4 mesothelioma cases (not separately coded
before 1999))
SMR = 10.92 (2.98–27.96)
Berman et al. [2]: Meta-analysis from 11 cohort studies
providing type of fibers
SMR amphibole = 13.8 (3.5–26.3)
Group 1. Sufficient evidence for this
site.
(Vol. 100 C, 2012)
Reproductive cancers
Epithelial tumors of
the male breast
Alkylphenolic
compounds
Villeneuve et al. [64]: European case control study (104
cases and 1901 controls)
OR = 3.8 (1.5–9.5) among subjects exposed above the
median, adjusted for age, country, alcohol consumption,
body mass index and education
Not classified.
Gasoline and
combustion
products
Hansen et al. [63]: Nationwide register based case
control study on male breast cancer morbidity (230
cases and 12,880 control)
OR = 2.5 (1.3–4.5) adjusted for birth year and
socioeconomic status
Gasoline engine exhaust classified
group 2B.
(Vol. 105, in prep, meeting in 2012)
Epithelial tumors of
the cervix uteri
Organic solvents Weiderpass et al. [65]: Register linkage study in
Finland among 413,877 female workers born
(1906–1945), 1101 cervical cancer cases
Aliphatic and alicyclic solvents RR = 1.3 (1.1–1.6)
Aromatic-hydrocarbon solvents RR = 1.2 (1.1–1.4)
Chlorinated-hydrocarbon solvents RR = 1.3 (1.0–1.7)
No classification for this site.
Trichloroethylene Wartenberg et al. [50]: Review on trichloroethylene
and cancer (over 80 papers)
SMR (from 4 mortality studies) average risk 1.7
(1.5–2.0)
SIR (one cohort study) 2.4 (1.1–4.8)
Group 1. No evidence for this site.
(Vol. 106, 2012)
Metalworking
fluids
Betenia et al. [66]: Cohort of 4374 female autoworkers
followed from 1985–2004
SIR = 2.96 (2.11–4.02) based on 40 cases
No classification for this site.
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Ovarian cancer Asbestos Camargo et al. [67]: Meta-Analysis including 18
studies
SMR 1.77 (1.37–2.28)
Group 1.
Sufficient evidence for this site.
(Vol. 100 C, 2012)
Silica dust Wernli et al. [68]: Nested case control study 261
incident ovarian cancer cases and 3121 control women
RR = 5.6 (1.4–23.6) among women exposed 10 years or
more, adjusted for age and reproductive category
Group 1. No mention to this specific
site.
Diesel exhaust Guo et al. [69]: Register-linkage study in Finland
among female workers born 1906–1945
RR = 3.7 (1.4–9.9) among highest exposure group
(≥10.0 mg/m3-years) adjusted for mean number of
children, body mass index, socioeconomic status, age
and calendar period; p for trend 0.006
Group 1. No evidence for this
specific site.
(Vol. 105, in prep, meeting in 2012)
Trichloroethylene Morgan et al. [70]: Cohort of 20,508 aerospace
workers (13 cases), 4733 with occupational exposure to
trichloroethylene (8 cases)
High cumulative exposure RR = 7.1 (2.1–23.5), no
adjustment
Group 1. No evidence for this site.
(Vol. 106, in prep, meeting in 2012)
Urogenital cancers
Non-bladder urinary
organs (renal
pelvis, ureter,
urethra)
Polycyclic
aromatic
hydrocarbons
(PAH)
Jensen et al. [75]: Hospital-based case control study
(96 cases (renal pelvis, ureter) 294 controls)
Coke, coal OR = 4.0 (1.2–13.6); Asphalt, tar OR = 5.5
(1.6–19.6), adjusted for sex and lifetime tobacco
consumption
Group 1. No classification for this
site.
Coal-tar pitch: limited evidence for
bladder cancer, no classification for
this site.
(Vol. 100 F, 2012)
Neuroectodermic and mesodermic tumors
Epithelial tumors of
the eye and adnexa
Ultraviolet
radiation
Vajdic et al. [76]: Population-based case control study
in Australia (290 cases, 893 controls)
Highest category of GSR-weighted (MJ/m2)
occupational outdoor hours during decade years
OR = 2.1 (1.2–3.7) adjusted for age, region of birth, eye
color, ability to tan and squinting as a child
UV-emitting tanning devices
classified group 1 with sufficient
evidence for this site.
(Vol. 100 D, 2012)
Welding classified Group 1 with
sufficient evidence for eye.
(Vol. 100 D, 2012)
Håkansson et al. [77]: Cohort study on sunlight
exposure and cancer incidence in the Swedish
construction industry including 323,860 men (35 eye
melanoma cases)
Ocular melanoma in the highest exposed group RR = 3.4
(1.1–10.5) adjusted for age, smoking, and magnetic
field exposure
Malignant melanoma
of the uvea
Guénel et al. [78]: French part of a European Case
control study (50 cases, 479 controls)
Ocular melanoma among men welders age adjusted
OR = 7.3 (2.6–20.1) and dose-response relationship with
job duration
Soft-tissue sarcoma PolyChloroPhenol Hoppin et al. [79]: Population-based case control study
among men (295 cases, 1908 controls)
Odds ratios were adjusted for age, registry, race,
medical radiations and exposure to herbicides
High-intensity exposure OR = 1.79 (1.10–2.88).
Duration-response trend (p for trend < 0.0001)
10 years of substantial exposure or more, OR = 7.78
(2.46–24.65)
Group 2B. Limited evidence for this
site.
(Vol. 71 and 100 F, 2012)
2,3,7,8-
Tetrachloro-
dibenzo-p-dioxin
Fingerhut et al. [80]: Cohort mortality study among
5172 workers at 12 plants in the United States that
produced chemicals contaminated with TCDD
SMR = 922 (190–2695)
Collins et al. [81]: Cohort study of 1615 workers
exposed to dioxins in trichlorophenol production
SMR = 4.1 (1.1–10.5)
Group 1. Limited evidence for STS.
(Vol.100 F, 2012)
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Bone sarcoma Ionizing radiation Carnes et al. [9]: cohort studies of 820 women working
as radium watch-dial painters (46 bone sarcomas)
Dose response relationships for bone sarcoma mortality:
p < 0.001
Group 1. Sufficient evidence for this
site.
(Vol. 100 D, 2012)
Pesticides Merletti et al. [83]: Multicenter case control study in 7
European countries. 96 bone sarcoma cases compared to
2632 controls
OR adjusted for age, country, gender and number of job
periods: 2.61 (1.49–4.57)
Malignant
meningioma
Lead (inorganic) Rajaraman et al. [95]: Case control study of 197
meningioma cancers and 799 non-cancer controls
In subject with ALAD2 variant allele and exposed to
100 g/m3-year, OR = 12.8 (1.4–120.8)
Navas-Acien et al. [96]: Historical cohort of all
Swedish men and women
RR = 2.36 (1.12–4.96) in male workers with possible
exposure to lead (adjusted for age, Period, Geographical
Category and Town Size and exposure to other
chemicals)
Group 2 A.
(Vol. 87, 2006)
Endocrine tumors
Carcinoma of the
thyroid gland
Ionizing radiations Zielinski et al. [98]: Cohort study of the Canadian
national dose registry of radiation workers
SIR = 1.74 (1.40–2.10)
Zabel et al. [100]: Among workers exposed more than
5 years prior to 1950: RR = 3.04 (1.01–10.78)
Group 1. Sufficient evidence for
thyroid cancer in Atomic-bomb
survivors, medical patients.
(vol. 100 D, 2012)
Organic solvents Lope et al. [101]: Cohort of 2,992,166 Swedish workers
employed in the 1970 census (2599 TC)
Probable exposure to organic solvents among women,
RR = 1.91 (1.05–3.45) after adjustment for exposure to
ionizing radiations
Lymphoid diseases
Hodgkin disease Pesticides Karunanayake et al. [104]: Population-based, case
control study (316 Hodgkin Lymphoma and 1506
controls). Adjustment for age, province of residence,
medical and family history, use of other pesticides,
correlated with chlorpyrifos use.
Exposure to insecticide chlorpyrifos OR = 1.19
(1.03–1.37) All other pesticides showed not significant
association or no association
Orsi et al. [102]: Hospital based case control study (491
cases (87 HD); 456 controls); Analysis adjusted for age,
socioeconomic category
Fungicides OR 4.5 = (1.6–12.2); organochlorine
OR = 4.7 (1.1–20.8)
Organophosphate OR = 3.0 (1.0–9.4); Pyrethrin
OR = 3.6 (1.2–11.2)
Phenoline herbicide OR = 4.3 (1.1–17.2); Picoline
OR = 9.4 (2.0–43.1)
Amide OR 3.8 = (1.1–12.7); Urea herbicide OR = 10.8
(2.4–48.1)
Khuder et al. [103]: Meta-analysis of 30 peer-reviewed
studies.
Occupational exposure as farmer: combined RR = 1.25
(1.11–1.42); 13 case–control studies: combined
RR = 1.53 (1.18–1.98);
7 cohort studies combined RR = 1.08 (0.97–1.20);
10 mortality and morbidity studies: combined RR = 1.18
(1.02–1.36)
No classification for this site.
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Wood dust Briggs et al. [105]: Population-based case control study
(343 Hodgkin disease and 1910 controls)
OR = 4.6 (1.6–13.3), adjusted for age and race
Group 1. No classification for this
site.
(Vol. 100 C, 2012)
Acute lymphoblastic
leukemia
Benzene Vlaanderen et al. [107]: MA of 44 studies (17 studies
for ALL with 47 ALL cases). Meta-RR = 1.44 (95%CI
1.03–2.02)
Group 1. Limited evidence for ALL.
(Vol. 100 F, 2012)
Diffuse large B-cell
lymphoma
(DLBCL)
Solvents Cocco et al. [113]: Multicenter case-control study
(2348 lymphoma cases (251 FL)/2462 controls).
Adjustment for age, gender, education and center.
All solvents: OR = 1.0 (0.8–1.2), p trend NS
Wang et al. [117]: population-based case–control study
in women (601 NHL cases (189 DLBCL)/717 controls).
Adjustment for age, gender, education and center.
Organic solvents, medium-high intensity OR = 2.1
(1.4– 3.3), p trend < 0.01
Chlorinated solvents, medium-high intensity OR = 2.2
(1.4, 3.4), p trend < 0.01
Miligli et al. [120]: Population-based multicenter
case-control study (1428 NHL (308 DLBCL)/1530
controls); adjustment for sex, age, education, and area
Any solvent OR = 1.5 (1.0–2.1); Xylene
OR = 2.3(1.2–4.4); Toluene OR = 2.4 (1.3–4.6)
Limited evidence for Benzene Group
1. (Vol. 100 F, 2012)
Trichloroethylene
(TCE)
Purdue et al. [119]: population-based case–control
study (1189 cases (293 follicular lymphoma, 366
DLBCL), 982 controls). Adjustment for age, sex, race,
education level and area
TCE > 150 ppm–hr/week OR = 1.11 (1.01–1.23), p
trend = 0.03
TCE Cumulative exposure (estimated
ppm–hr) > 112,320 OR = 1.07 (0.94–1.22), p trend NS
Seidler et al. [115]: population-based case–control
study (710 malignant lymphoma (158 DLCBL)/710
controls) adjustment for smoking (in pack years) and
alcohol consumption
TCE >35 ppm*yrs.: OR = 2.6 (0.7–3.0), p trend 0.03
Group 1.
Limited evidence for lymphoma.
(Vol. 106, in prep, meeting in 2012)
Ethylene oxide Kiran et al. [136]: case–control study (2347 lymphoma
cases (530 DLCBL) and 2463 controls), adjustment for
age, sex, and participating center.
Ever exposure to ethylene oxide OR = 1.3 (0.6–2.9)
Exposed > 5% of working hours OR = 6.4 (1.8–23.0); p
trend 0.063
Group 1. Limited evidence for NHL.
(Vol. 100 F, 2012)
Follicular B
lymphoma (FL)
Solvents Cocco et al. [113]: Multicenter case–control study
(2348 lymphoma cases (251 FL)/2462 controls).
Adjustment for age, gender, education and center.
All solvents: OR = 1.3 (1.0–1.7), p trend < 0.001
Benzene, toluene and xylene combined: OR = 1.7
(1.2–2.5), p trend < 0.0001
Wang et al. [117]: population-based case-control study
in women (601 NHL cases (136 FL)/717 controls)
adjustment for age, family history of hematopoietic
cancers, alcohol, and race
Organic solvents, medium-high intensity OR = 1.3
(0.7–2.1), p trend NS
Seidler et al. [115]: population-based case–control
study (710 malignant lymphoma (92 FL)/710 controls)
adjustment for smoking (in pack years) and alcohol
consumption
Chlorinated hydrocarbons >47.3 ppm*yrs.: OR = 3.9
(1.3–12.1), p trend = 0.04
Limited evidence for Benzene Group
1. (Vol. 100 F, 2012)
Xylenes: Group 3.
Toluene: Group 3.
Dichloromethane: Group 2B.
1,2-Dicloroéthane Group 2B.
(Vol. 71, 1999)
114 B. Charbotel et al. / Critical Reviews in Oncology/Hematology 90 (2014) 99–134
Table 2 (Continued )
Cancer type Occupational
exposure
Risk level (95% confidence intervals) IARC Classification
Trichloroethylene
(TCE)
Purdue et al. [119]: population-based case–control
study (1189 cases (293 follicular lymphoma, 293 FL),
982 controls). Adjustment for age, sex, race, education
level and area
TCE > 150 ppm–hr/week OR = 3.7 (1.2–11.7), p
trend = 0.005
TCE Cumulative exposure (estimated
ppm–hr) > 112,320 OR = 1.17 (1.04–1.32), p
trend = 0.01
Group 1.
Limited evidence for lymphoma.
(Vol. 106, in prep, meeting in 2012)
Hair cell leukemia Pesticides Orsi et al. [102]: Hospital based case control study (491
cases (27 HCL); 456 controls); Analysis adjusted for
age, socioeconomic category.
Occupational exposure to organochlorine insecticides
OR = 4.9 (1.1–21.2); Herbicides (Picoline OR = 4.1
(1.1–15.5), Triazine OR = 5.1 (1.4–19.3).
Clavel et al. [122]: Hospital based case control study
(226 HCL, 425 controls). Possible or definite
occupational pesticides exposure OR = 1.5 (1.0–2.3).
Definite organochlorines exposure OR = 2.1 (1.2–3.7);
Definite organophosphorus exposure OR = 2.6 (1.1–57)
Definite herbicide exposure OR = 2.0 (1.1–3.5); definite
exposure to Triazine OR = 2.4 (1.2–4.8)
Definite organic fungicides exposure OR = 2.9
(1.5–5.3); Duration of definite exposure to organic
fungicides OR = 2.6 (0.9–7.5) and OR = 3.5 (1.4–8.3),
for <10 years and >10 years of exposure respectively.
After adjustment for smoking: OR = 7.5 (0.9–61.5) for
exposure to organophosphorus insecticides, OR = 2.8
(1.4–5.6) for forage growing in non-smokers.
Nordström et al. [123]: Population-based case-control
study (121 male HCL; 484 controls) Exposure to
herbicides OR = 2.9 (1.4–5.9), insecticides OR = 2.0
(1.1–3.5), fungicides OR = 3.8 (1.4–9.9), impregnating
agents OR = 2.4 (1.3–4.6).
After adjustment for age: herbicides OR = 1.8 (0.7–4.6),
insecticides OR = 0.7 (0.3–3.7), fungicides OR = 2.1
(0.6–6.5), impregnating agents OR = 2.0 (1.0–3.9).
Group 2A: occupational exposures to
non-arsenical insecticides (spraying
and application) (Vol. 53, 1991)
Several compounds classified 2B or 3
(Vol. 5 sup 7, 1987; Vol. 30, sup 7,
1987; Vol. 41, sup 7, 1987; Vol. 53,
1991)
No classification for this site.
Multiple myeloma
(MM)
Pesticides Perrotta et al. [129]: Systematic review of 55 case
control studies (1970–2007)
Working as a farmer pooled OR = 1.39 (1.18–1.65)
Working on a farm >10 years pooled OR = 1.87
(1.15–3.16)
Ever occupational pesticides exposure OR = 1.47
(1.11–1.94)
Herbicides exposure pooled OR = 2.19 (1.30–2.95)
Pahwa et al. [130]: Population-based case control study
(342 Multiple Myelomas and 1506 controls). Analysis
adjusted for age, province of residence, medical and
family history of MM, exposure to chemicals other than
pesticides
Carbamate insecticides OR = 1.81 (1.05–5.35)
Fungicide captan OR = 2.35 (1.03–5.35)
Orsi et al. [102]: Hospital based case control study (244
NHL (56 MM) and 456 controls); Analysis adjusted for
age, socioeconomic category
Occupational pesticides use OR = 3.5 (1.6–7.7);
Insecticides OR = 2.8 (1.2–6.5); Fungicides OR = 3.2
(1.4–7.2); Herbicides OR = 2.9 (1.3–6.5)
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Lope et al. [128]: Historical cohort (1971–1989;
2992,166 workers; linkage with National Cancer and
Death Registries). Multiple Myeloma 3127 men and
1282 women. Analysis adjusted for age, period and
geographical area
Male occupation in agriculture, forestry, and fishing
RR = 1.18 (1.07–1.30)
Male exposure to peaks of pesticides RR = 1.2
(1.07–1.34)
Pukkala et al. [73]: Historical cohort with record
linkage in 5 Nordic countries (15 Million people; MM
22,106 men, 19,508 females)
Male farmers SIR = 1.07 (1.03–1.11); female farmers
SIR = 1.14 (1.05–1.24)
Group 2A: (occupational exposures
to non-arsenical insecticides
(spraying and application)
(Vol. 53, 1991)
Several compounds classified B or 3
(Vol. 5, sup 7, 1987; Vol. 30, sup 7,
1987; Vol. 41, sup 7, 1987; Vol. 53,
1991)
No classification for this site.
Benzene Vlaanderen et al. [107]: Meta-analysis of 44 studies
(26 studies corresponding to 284 MM)
Meta-RR = 1.12 (0.98–1.27)
Infante et al. [125]: MA of 8 benzene cohorts (22
observed MM deaths)
SMR = 1.61 (1.01–2.44); pooled weighted RR = 2.13
(1.31–3.46)
Sonoda et al. [127]: Meta-analysis (8 case-control
studies)
Meta OR = 0.74 (0.60–0.90)
Group 1.Limited evidence for MM.
(Vol. 100 F, 2012)
Ethylene oxide Group 1. Limited evidence for MM.
(Vol. 100 F, 2012)
Engine exhaust Sonoda et al. [127]: Meta-analysis (7 case-control
studies)
OR = 1.34 (1.14–1.57)
Diesel engine exhaust Group 1.
Gasoline engine exhaust Group 2B.
(Vol. 105, 2012)
No classification for this site.
Chronic lymphocytic
leukemia
(CLL)/small
lymphocytic
lymphoma (SLL)
Benzene Schnatter et al. [135]: pooled analysis of 3 cohort
studies (370 cases (80 CLL); 1587 controls)
OR = 1.49(0.81–2.75)
Vlaanderen et al. [107]: Meta-analysis of 44 studies
(18 studies for CLL with 111 CLL cases) meta-RR 1.14
(0.78–1.67)
Khalade et al. [134]: Meta-analysis of 15 (10 studies
for CLL) Summary effect-size OR 1.31 (1.09–1.57)
Group 1. Limited evidence for this
site.
(Vol. 100 F, 2012)
Solvents Cocco et al. [113]: Multicenter case-control study
(2348 lymphoma cases (323 CLL)/2462 controls).
Adjustment for age, gender, education and center;
Bonferroni correction for multiple testing
All solvents OR = 1.5 (1.1–1.9) p trend 0.000004;
Benzene, Toluene and Xylene combined OR = 1.4
(1.0–1.9); p trend 0.000048
Purdue et al. [119]: population-based case–control
study (1189 cases (141 CLL/SLL), 982 controls).
Adjustment for age, sex, race, education level and area
OR = 2.7 (1.2–5.8) p trend not significant.
Seidler et al. [115]: population-based case-control
study (710 malignant lymphoma 104 CLL/710 controls)
adjustment for smoking (in pack years) and alcohol
consumption, no positive association with solvents
found
Miligli et al. [120]: Population-based multicenter
case-control study (1428 NHL 285 CLL and small
lymphocytic lymphoma)/1530 controls); adjustment for
sex, age, education, and area
Dichloromethane OR = 3.2 (1.0–10.1); Toluene
OR = 2.0 (1.0–4.0)
No IARC classification for this site.
Xylenes: Group 3.
Toluene: Group 3.
Dichloromethane: Group 2B.
(Vol. 71, 1999)
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Cancer type Occupational
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Risk level (95% confidence intervals) IARC Classification
Ethylene oxide Kiran et al. [136]: case–control study (2347 lymphoma
cases (406 CLL) and 2463 controls), adjustment for age,
sex, and participating center.
Ever exposure to ethylene oxide OR = 2.0 (0.8–4.7)
Exposed >5% of working hours OR = 6.2 (1.3–29.3),
p trend 0.028
Group 1. Limited evidence for CLL.
(Vol. 100 F, 2012)
1,3-Butadiene Sielken et al. [138]: cohort study 16,585 workers
(12,819 workers exposed). 81 leukemia mortalities, 71
among exposed workers.
Slope per cumulative ppm-years, β = 0.000417,
p = 0.000027
Group 1.
Sufficient evidence for
haematolymphatic organs. No
specific classification for this
subtype.
(Vol. 100 F, 2012)
Marginal zone
lymphoma/MALT
lymphoma
Solvents Seidler et al. [115]: population-based case–control
study (710 malignant lymphoma (38 marginal zone
lymphoma)/710 controls) adjustment for smoking (in
pack years) and alcohol consumption
High occupational exposure to chlorinated
hydrocarbons OR = 7.0 (1.8–26.3)
No IARC classification.
Acute myeloid
leukemia
Benzene Vlaanderen et al. [124]: Meta-analysis of (21 studies
with 217 AML cases) Meta RR 1.68(1.35–2.10)
Khalade et al. [134]: Meta-analysis of 15 studies (9
studies for AML) Summary effect-size 1.38 (1.15–1.64)
Group 1.
Sufficient evidence for this site.
(Vol 100F, 2012)
Pesticides Van Maele Fabry et al. [146]: Meta-analysis of 17
cohort and 16 case-control studies
Meta RR = 1.55 (1.02–2.34)
Group 1: Arsenic (Vol. 100 C, 2012)
Group 2A: Occupational exposures to
non-arsenical insecticides (spraying
and application) (Vol. 53, 1991)
Captafol (Vol. 53, 1991)
Several compounds classified 2B or 3
(Vol. 5, sup 7, 1987; Vol. 30, sup 7,
1987;
Vol. 41, sup 7, 1987; Vol. 53, 1991)
No classification for this site.
Formaldehyde Zhang et al. [132]: Meta-analyses of 21 studies (4
studies with myeloid leukemia subtype specific data)
Meta RR for myeloid leukemia = 2.47 (1.42–4.27)
Group 1.
Sufficient evidence for leukemia. No
specific classification for this
subtype.
(Vol. 100 F, 2012)
Radiation Daniels et al. [145]: nested case-control study in
nuclear worker cohort (369 leukemia deaths (150 AML)
in 105,245 US nuclear workers)
AML in the 6–14-years window (ERR per
100 mGy = 7.0 (0.079–32.0); adjusted for sex, race and
hire year
Group 1.
Sufficient evidence for leukemia. No
specific classification for this
subtype.
(Vol. 100 D, 2012)
Chronic myeloid
leukemia
Formaldehyde Zhang et al. [132]: Meta-analyses of 21 studies (4
studies with myeloid leukemia subtype specific data)
Meta RR for myeloid leukemia = 2.47 (1.42–4.27)
Group 1.
Sufficient evidence for myeloid
leukemia.
(Vol. 100 F, 2012)
Radiation Daniels et al. [145]: nested case–control study in
nuclear worker cohort (369 leukemia deaths (52 CML)
in 105,245 US nuclear workers)
CML (ERR per 100 mGy = 0.29 (<0 to 1.8); adjusted for
sex, race and hire year
Group 1.
Sufficient evidence for leukemia.
(Vol. 100 D, 2012)
Other
myelo-dysplastic
and
myelo-proliferative
neoplasms
Benzene Schnatter et al. [135]: pooled analysis of 3 cohort
studies (370 cases (29 myelodysplastic syndromes
(MDS) and 30 myeloproliferative disorders (MPD),
1587 controls)
Cumulative exposure >2.93 ppm–years high and
medium certainty diagnoses MDS OR = 4.33
(1.31–14.3); MPD OR = 1.79(0.68–4.74)
Group 1.
No classification for this site.
(Vol. 100F, 2012)
B. Charbotel et al. / Critical Reviews in Oncology/Hematology 90 (2014) 99–134 117
Table 2 (Continued )
Cancer type Occupational
exposure
Risk level (95% confidence intervals) IARC Classification
Childhood leukemia Parental
occupational
pesticides
exposure
Vinson et al. [164]: Meta-analysis of 40 studies: 3
cohort studies: OR = 0.95 (0.81–1.11); 37 case control
studies:
Paternal occupational exposure OR = 1.37 (1.23–1.52);
Paternal exposure during prenatal period (occupation
and environmental) OR = 1.32 (1.20–1.46); Maternal
exposure during prenatal period (occupation and
environmental) OR = 1.48 (1.26–1.75); Parental
exposure to insecticides OR = 1.17 (1.03–1.33); Parental
exposure to herbicides OR = 1.26 (1.14–1.39)
Van Maele-Fabry et al. [162]: Meta-analysis of 25
studies: Maternal occupational exposure meta RR = 1.62
(1.22–2.16); Paternal occupational exposure meta
RR = 1.14 (0.76–1.69)
Wigle et al. [163]: Meta-analysis of 30 studies:
Maternal occupational exposure (16 studies) OR = 2.09
(1.51–2.88)
Paternal occupational exposure (30 studies) OR = 1.09
(0.88–1.34)
Group 1: Arsenic (Vol. 100 C, 2012)
Group 2A: application of
non-arsenical pesticides.
Captafol (Vol. 53, 1991), Several
compounds classified 2B or 3 (Vol. 5,
sup 7, 1987;
Vol. 30, sup 7, 1987;
Vol. 41, sup 7, 1987; Vol. 53, 1991)
No classification for this site.
Painting Schuz et al. [157]: Case control study (1138 ALL/2962
controls): Maternal pre-conceptional occupational
exposure: OR = 1.6 (1.1–2.4) and during pregnancy:
OR = 2.0 (1.2–3.3). Adjusted for socioeconomic status
and degree of urbanization
Shu et al. [155]: Case control study including 1842
ALL and 1986 controls.
Maternal occupational exposure pre-conceptional
OR = 1.6 (1.1–2.3) and during pregnancy OR = 1.7
(1.2–2.3). Adjusted for maternal education, race, and
family income
Buckley et al. [154]: Case control study with 204
AML/ANLL)
Maternal exposure OR = 2.2 (0.9–5.4), prolonged spray
paints exposure OR = 3.0 (trend, p = 0.03). Adjusted for
other professional exposure
Lowengart et al. [158]: registry based case control
study (123 acute leukemia cases, 123 controls) paternal
exposure after delivery to spray paint OR = 2.2
(0.96–4.39). No information on adjustment variables
Van Steensel-Moll et al. [153]: Registry based case
control study (519 ALL, 507 controls)
Maternal occupational exposure during pregnancy
RR = 2.4 (1.2–4.6)
Group 1. Limited evidence for this
site.
(Vol. 100 F, 2012)
Solvents Castro-Jimmenez et al. [165]: Case control study (85
ALL and 85 individually matched neighborhood
controls)
Parental occupational exposure to hydrocarbons during
24 months before conception: mother only OR = 6.33
(1.41–28.31), both parents OR = 13.47 (3.31–54.71);
adjustment for maternal age at child’s birth, parental
pre-conception smoking status, and maternal
socioeconomic status during index pregnancy
Infante-Rivard et al. [167]: Population-based
case–control study (790 childhood ALL, 790 healthy
controls)
Maternal occupational exposure to solvents before and
during pregnancy, adjusted for maternal age and sex.
OR = 1.11 (0.88–1.40); mononuclear aromatic
hydrocarbons OR = 1.64 (1.12–2.41)
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Mc  Kinney et al. [159]: Registry-based case control
study (40,647 female workers, 47 childhood cancers);
Childhood leukemia RR = 3.83 (1.17–12.55); all
childhood malignancies RR = 2.26 (1.12–4.54)
peri-conceptional maternal occupational exposure
Schuz et al. [157]: Case control study (1138 ALL/2962
controls)
Maternal occupational exposure pre-conceptional:
OR = 1.2 (0.9–1.7) and during pregnancy: OR = 1.3
(0.8–1.9). Adjusted for socioeconomic status and degree
of urbanization
Smulevitch et al. [168]: Population-based case control
study including 593 childhood cancers and 1181
controls Maternal occupational exposure OR = 3.1
(1.5–6.3) adjusted for parental alcohol consumption
Shu et al. [155]: Case control study 1842 ALL and
1986 controls)
Maternal occupational exposure pre-conception
OR = 1.8 (1.3–2.5); during pregnancy OR = 1.6
(1.1–2.3) adjusted for maternal education, race, and
family income
Buckley et al. [154]: Case control study including 204
AML/ANLL
Paternal exposure OR = 2.0 (1.2–3.8), adjusted for other
professional exposures
Lowengart et al. [158]: Registry based case control
study (123 acute leukemia cases and 123 controls)
Paternal exposure after delivery to chlorinated solvents
OR = 3.5 (1.1–14.6). No information on adjustment
variables
No IARC classification for this site.
Xylenes: Group 3.
Toluene: Group 3.
Dichloromethane: Group 2B.
1,2-Dicloroéthane Group 2B.
(Vol. 71, 1999)
Wood work Feychting et al. [160]: Birth cohort (235,635 children,
161 leukemias), registry linkage study
Paternal pre-conceptional occupation in wood work
RR = 2.18 (1.26–3.78). Adjusted for maternal age,
socio-economic status, census year and gender
Group 1.
No IARC classification for this site.
(Vol. 100 C, 2012)
Childhood lymphoma Pesticides Vinson et al. [164]: Meta-analysis of 40 studies
Paternal prenatal exposure (9 studies) OR = 1.37
(1.16–1.61)
Maternal prenatal pesticides exposure (5 studies)
OR = 1.53 (1.22–1.91)
Ever exposure mother (6 studies) OR = 1.90 (1.14–3.17)
Parental exposure to insecticides (11 studies) OR = 1.46
(1.20–1.78)
Parental exposure to herbicides (4 studies) OR = 1.31
(1.02–1.67)
Parental exposure to fungicides (3 studies) OR = 1.45
(1.06–1.99)
No IARC classification for this site.
Ewing sarcoma Pesticides Vinson et al. [164]: Meta-analysis
Paternal occupational exposure (3 case control studies)
OR = 2.34 (1.33–4.12); Maternal occupational exposure
non-significant increased risk
Valery et al. [186]: Meta-analysis of 5 case control
studies with 199 cases and 1451 controls
Paternal farm work OR = 2.3 (1.3–4.1) and maternal
farm work OR = 3.9 (1.6–9.9) during pre-conception
and gestation period
After adjustment for farm residency OR = 1.4 (0.3–6.2)
and OR = 1.7 (0.7–4.0) respectively
No IARC classification for this site.
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Childhood brain
tumor
Pesticides Vinson et al. [164]: Meta-analysis of 40 studies
Paternal occupational exposure (11 case control studies)
OR = 1.40 (1.20–1.62); Maternal occupational exposure
non-significant
Paternal prenatal exposure (9 studies/OR) OR = 1.49
(1.23–1.79); Maternal prenatal exposure non-significant
Parental exposure to herbicides (16 studies/OR)
OR = 1.31(1.08–1.60)
Parental exposure to insecticides (24 studies/OR)
OR = 1.18 (1.06–1.33)
Parental exposure to fungicides (15 studies/OR)
OR = 1.32 (1.06–1.65)
Kristensen et al. [175]: Registry based cohort study
including 323,292 children and 1275 cancer
Parents farm holders, risk adjusted for year of birth and
calendar year
Risk of brain tumors (n = 41) RR = 1.71 (1.11–2.63)
Risk of non-astrocytic neuroepithelial tumors (n = 22)
RR = 3.37 (1.63–6.94)
Feychting et al. [160]: Registry linkage study (235 635
children, 162 nervous system tumors) paternal
pre-conceptional occupational exposure to pesticides
RR = 2.36 (1.27–4.39), adjusted for maternal age,
socio-economic status, census year and gender
No IARC classification for this site.
Painting Feychting et al. [160]: Registry linkage study (235 635
children, 162 nervous system tumors) paternal
pre-conceptional work as painter RR = 3.65 (1.71–7.80)
Adjusted for maternal age, socio-economic status,
census year and gender
Group 1.
No classification for this site.
Polycyclic
aromatic
hydrocarbons
(PAH)
Cordier et al. [179]: Case control study including 1218
cases and 2223 controls); adjusted for maternal age, sex
of child, mother’s level of education
Paternal pre-conceptional occupational exposure to PAH
All childhood brain tumors OR = 1.3 (1.1–1.6)
Astroglial tumors OR = 1.4 (1.1–1.7)
Astroglial tumors after exclusion of smoking fathers
OR = 1.7 (1.3–2.3)
Maternal occupational exposure OR = 1.11 (0.88–1.40
Johnson et al. [178]: Case control study with 499
childhood death from intracranial or spinal cord tumors
and 998 controls
Parental occupation with high PAH exposure: printers
and graphics arts workers OR = 4.5 (1.4–14.7); chemical
and petroleum workers levels: OR = 3.0 (1.1–8.5)
Some PAH-related exposures are
Group 1 but none of them for this site
of cancer.
(Vol. 100 F, 2012)
Diesel exhaust Peters et al. [180]: Case control study including 306
cases and 950 controls
Maternal exposure before child’s birth OR = 2.03
(1.09–3.81) and paternal exposure around the time of
the child’s conception OR = 1.62 (1.12–2.34)
Group 1. No classification for this
site.
(Vol. 105, in prep, meeting in 2012)
N : Meta-
51)
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teuro-blastoma Parental exposure
to pesticides
Vinson et al. [164]
OR = 1.70 (1.14–2.
.1.5.  Epithelial  tumors  of  the  larynx*
IARC has classified asbestos and acid mists as car-
inogenic for larynx (sufficient evidence) as well as the
ubber industry (limited evidence) [10,22,23]. The associ-
tion with asbestos is supported by numerous studies and meta-analysis [24,25]. Furthermore, meta-analyses have
een conducted for several other occupational risks. Thus,
hen et al. reported evidence for an association with silica
a
fi
ganalysis No IARC classification for this site.
ust, although only the pooled risk from case–control studies
as statistically significant [26]. Moreover, Paget-Bailly et al.
dentified significant increased meta-relative risks associated
ith polycyclic aromatic hydrocarbons, engine exhaust, and
extile dust [27]. A relationship with wood dust exposure has
lso been suggested, but a meta-analysis did not confirm this
nding [27]. Similarly, although laryngeal cancer was sug-
ested to be linked to chlorinated solvent exposure, this could
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Table 3
Summary of the available evidence by cancer site.
Cancer type Occupational exposure
(Group 1 carcinogen) with
sufficient evidence supported
by IARC classification
Occupational exposure with
limited evidence supported by
IARC classification or evidence
from meta-analysis (a)
Comments
Head and neck cancers
Cancer of the nasal cavity and
sinuses
Wood dust, Nickel, Leather
dust, Isopropyl alcohol
production, radium
Formaldehyde, Chromium,
carpentry and joinery, textile
manufacturing
Naso-pharyngeal cancer (NPC) Formaldehyde, Wood Dust
Cancers of the salivary gland Insufficient evidencec
Hypo-pharyngeal cancer Asbestos
Laryngeal cancer Asbestos, Acid mists Rubber industry
Passive smoking at work, Sulfur
mustard, Engine exhausta, Silica
dusta, Polycyclic aromatic
hydrocarbonsa, Textile dusta
Pharyngeal/Oropharyngeal cancer Insufficient evidence
Cancer of the oral cavity Insufficient evidence
Cancer of the lip Outdoor work (solar radiations)
Gastrointestinal cancers
Squamous cell carcinoma of the
esophagus
Insufficient evidence;
Covered by the IARC
classification for esophagus
cancerb
Adenocarcinoma of the esophagus Insufficient evidence;
Covered by the IARC
classification for esophagus
cancerb
Carcinoma of the small intestine Insufficient evidence
Cancer of the anal canal No relevant data identified
Hepatocellular carcinoma of the
liver and intrahepatic bile tract
(IBT)
Vinyl chloride monomer,
Plutonium, Thorium,
Aflatoxin, Hepatitis B,
Hepatitis C
Polychlorinated biphenyls,
Trichloroethylene, Arsenic
Radon in underground minersa
Hepatic angiosarcoma* Vinyl chloride monomer
Epithelial tumors of gallbladder
and extrahepatic biliary tract
(EBT)
Insufficient evidence
Thoracic cancers
Epithelial tumor of the trachea No relevant data identified
Large cell lung carcinoma Asbestos, Diesel exhaust Covered by the IARC
classification for lung cancerb
Bronchiolo-alveolar lung
carcinoma
No relevant data identified
Epithelial tumors of the thymus No relevant data identified
Mesothelioma Asbestos, Erionite, Painting
Reproductive cancers
Mammary Paget’s Disease No relevant data identified
Epithelial tumors of the male
breast
Insufficient evidence;
Covered by the IARC
classification for breast
cancerb
Epithelial tumors of the cervix
uteri
Insufficient evidence
Ovarian cancer Asbestos
Tumors of the vulva and vagina No relevant data identified
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Cancer type Occupational exposure
(Group 1 carcinogen) with
sufficient evidence supported
by IARC classification
Occupational exposure with
limited evidence supported by
IARC classification or evidence
from meta-analysis (a)
Comments
Urogenital cancers
Testicular cancer Insufficient evidence
Extragonadal germ cell tumors No relevant data identified
Penis carcinoma No relevant data identified
Squamous cell carcinoma of the
kidney
No relevant data identified;
Covered by the IARC
classification for kidney
cancerb
Non-transitional cell carcinoma of
the urinary bladder
No relevant data identified;
Covered by the IARC
classification for bladder
cancerb
Non-bladder urinary organs (renal
pelvis, ureter, urethra)
Aristochloric acid PAH Transitional cell carcinoma of
non-bladder urinary organs
are covered by IARC
classification for bladder
cancerb
Neuroectodermic and mesodermic tumors
Malignant melanoma of mucosa No relevant data identified
Epithelial tumors of the eye and
adnexa
Welding Solar radiation
Malignant melanoma of uvea Welding Solar radiation
Soft-tissue sarcoma Polychlorophenol, 2,3,7,8-
tetrachloro-dibenzo-p-dioxin
Bone sarcoma Ionizing radiation
Glial tumors of the central nervous
system
Insufficient evidence
Malignant meningioma Insufficient evidence
Neuroendocrine tumors No relevant data identified
Endocrine tumors
Carcinoma of the pituitary gland No relevant data identified
Carcinoma of the thyroid gland Insufficient evidence
Carcinoma of the parathyroid
gland
No relevant data identified
Carcinoma of the adrenal gland No relevant data identified
Lymphoid diseases
Hodgkin disease Insufficient evidence
Acute lymphoblastic leukemia Benzene
Burkitt lymphoma No relevant data identified;
Cutaneus T cell
lymphoma/mycosis fungoides
Insufficient evidence
Other T cell lymphoma and NK
cell neoplasms
Insufficient evidence;
Covered by the IARC
classification for lymphomab
Diffuse large B-cell lymphoma
(DLBCL)
Benzene, Trichloroethylene Covered by the IARC
classification for lymphomab
Follicular B lymphoma (FL) Benzene, Trichloroethylene Covered by the IARC
classification for lymphomab
Hair cell leukemia Insufficient evidence;
Covered by the IARC
classification for lymphomab
Multiple myeloma (MM) Benzene, Ethylene oxide
Pesticidesa
Other non-Hodgkin, mature B cell lymphoma
Chronic lymphocytic leukemia
(CLL)/small lymphocytic
lymphoma (SLL)
Benzene, Ethylene oxide Insufficient evidence for SLL
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Table 3 (Continued )
Cancer type Occupational exposure
(Group 1 carcinogen) with
sufficient evidence supported
by IARC classification
Occupational exposure with
limited evidence supported by
IARC classification or evidence
from meta-analysis (a)
Comments
Marginal zone lymphoma/MALT
lymphoma
Insufficient evidence;
Covered by the IARC
classification for lymphomab
Mantle cell lymphoma No relevant data identified;
Covered by the IARC
classification for lymphomab
Lymphoplasma-citic
lymphoma/macroglobulinemia
Waldestrom
No relevant data identified
Acute myeloid leukemia Benzene, Formaldehyde
Chronic myeloid leukemia Formaldehyde, Radiation
Other myelodysplastic and
myeloproliferative neoplasms
Insufficient evidence
Histiocytic and dendritic cell
neoplasms
No relevant data identified
Childhood cancer
Childhood leukemia Parental exposure to paintings
Parental pesticides exposurea
Childhood lymphoma Parental pesticides exposurea
Childhood brain tumor Parental pesticides exposurea
Neuroblastoma Insufficient evidence
Ewing sarcoma Parental pesticides exposurea
Wilms’ tumor Insufficient evidence
Other childhood cancer Insufficient evidence
a Supported by meta-analyses.
b http://monographs.iarc.fr/ENG/Classification/index.php (accessed October 2013).
c Insufficient evidence for association with occupational exposure.
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hot be verified in a review of the literature [21,27]. Machin-
ng fluids have also been associated with laryngeal cancer,
ut results are inconsistent [27]. Finally, several carcinogens
hat are known to affect other sites have been reported to
ncrease the risk of laryngeal cancer, including second hand
moke and ionizing radiation [28,29], whereas other sug-
ested occupational factors might be seen as more anecdotal
e.g., extremely low frequency magnetic fields) [30].
.1.6.  Epithelial  tumors  of  the  oropharynx**
Few studies have focused on oropharyngeal cancers
eparately. When considering pharyngeal cancers, some
ccupational factors have been identified in the literature (i.e.,
ulfur mustard [31] and welding fumes [32]).
.1.7. Epithelial  tumors  of  the  oral**  cavity  and  lip*
IARC classified solar radiations as carcinogenic for lip
limited evidence). Wood dust has been suggested as a risk
actor for cancer of the oral cavity [33]. Additionally, there
s an increased risk of lip cancer associated with outdoor
ccupations (e.g., construction workers, seafarers, farmers)
34] and outdoor occupational activities [35].
a
o
a
n.2.  Gastrointestinal  cancers
.2.1.  Squamous  cell  carcinoma  and  adenocarcinoma  of
he esophagus**
IARC classified dry cleaning and rubber industry pro-
uction as carcinogenic for esophagus (no distinction of
istology subtype) with limited evidence [10].
For squamous cell carcinoma, associations with several
gents have been suggested, including carbon black, sulfuric
cid, asbestos, and polycyclic aromatic hydrocarbons (PAHs)
32,36]. On the other hand, adenocarcinoma has been linked
o sulfur compounds and lead [37].
.2.2.  Carcinoma  of  the  small  intestine**
IARC has classified asbestos as carcinogenic for colon
nd rectum with limited evidence [10]. Nevertheless, a cohort
tudy found a significant increase in the risk of small intestine
ancer among men highly exposed to asbestos [38]. Addi-
ionally, an increased risk of small bowel adenocarcinoma
as been found among workers exposed to semiautomatic
rc welding [39]. However, no significant association was
bserved with other categories of welding or with welding
ctivity in general. An elevated risk of small bowel carci-
oid tumors was also reported for organic solvent-exposed
 in Onco
w
o
e
3
3
i
c
(
d
p
f
t
i
o
l
s
v
a
i
t
h
w
a
3
t
a
a
s
3
b
a
e
a
3
3
3
a
m
a
c
c
p
i
p
d
s
o
f
b
t
s
a
t
s
w
l
3
3
3
c
H
a
s
r
b
3
3
3
d
e
i
m
h
g
o
a
c
b
n
[B. Charbotel et al. / Critical Reviews
orkers [40]. More recently, an increased risk for cancer
f the small intestine has been suggested among workers
xposed to benzidine [41].
.2.3. Epithelial  tumors  of  the  anal  canal
No relevant data identified.
.2.4.  Hepatocellular  carcinoma  of  the  liver  and
ntrahepatic bile  tract  (IBT)*
IARC has classified several occupational exposures as
arcinogens for liver and bile duct with sufficient evidence
aflatoxin, hepatitis B and C, plutonium, thorium-232 and its
ecay products, vinyl chloride) or limited evidence (arsenic,
olychlorinated biphenyls, and trichloroethylene).
Aflatoxin is known to induce liver cancer, mainly via
ood contamination. However, workplace exposure to afla-
oxin was also suggested to increase the risk of liver cancer
n workers in the animal-feed processing industry [42] and
ther occupations [43,44].
Several other occupational exposures have been linked to
iver cancer, in particular vinyl chloride monomer, organic
olvents and polychlorinated biphenyls [45–52]. In fact,
inyl chloride monomer has been known to induce hepatic
ngiosarcoma for decades, and epidemiological studies have
dentified the association of this type of exposure with hepa-
ocellular carcinoma [48]. An increased risk of liver cancer
as been observed in workers exposed to radon [53,54] as
ell as in plutonium workers [55]. Magnetic fields were also
ssociated with cancer at this site [30].
.2.4.1.  Hepatic  angiosarcoma*.  IARC has concluded that
here is a causal relationship between hepatic angiosarcoma
nd vinyl chloride exposure (sufficient evidence). The strong
ssociation is supported by a positive dose–response relation-
hip [5,56].
.2.5.  Epithelial  tumors  of  gallbladder  and  extrahepatic
iliary tract  (EBT)**
IARC has classified thorium-232 and its decay products
s carcinogenic for this site with sufficient evidence. Radon
xposure has been reported to increase the risk of gallbladder,
nd extra hepatic bile ducts [54].
.3.  Thoracic  cancers
.3.1.  Epithelial  tumor  of  the  trachea
No relevant data identified.
.3.2.  Large  cell  lung  carcinoma*
IARC has classified numerous occupational exposures
s carcinogens for lung with sufficient evidence (alu-
inum production, arsenic and inorganic arsenic compounds,
sbestos, beryllium and compounds, bis(chloromethyl)ether;
hloromethyl, methyl ether, cadmium and compounds,
hromium(VI) compounds, coal, coal gasification, coal-tar
3
g
wlogy/Hematology 90 (2014) 99–134 123
itch, coke production, diesel engine exhaust, hematite min-
ng, iron and steel founding, nickel compounds, painting,
lutonium, radon-222 and its decay products, rubber pro-
uction industry, crystalline silica dust, soot, sulfur mustard,
econdhand tobacco smoke, X-radiation, gamma-radiation)
r limited evidence (strong inorganic acid mists, manu-
acture of glass, bitumens, exposure to oxidized and hard
itumens, carbon electrode manufacture, alpha-chlorinated
oluenes and benzoyl chloride, cobalt metal with tung-
ten carbide, creosotes, occupational exposures in spraying
nd application of insecticides, printing processes, 2,3,7,8-
etrachlorodibenzopara-dioxin, welding fumes) [10].
Few reports have distinguished cases based on histological
ubtype, and only two studies on large cell lung carcinoma
ere identified, which showed association with two common
ung carcinogens: asbestos and diesel exhaust [57,58].
.3.3. Bronchioloalveolar  carcinoma  of  the  lung
No relevant data identified.
.3.4.  Epithelial  tumors  of  the  thymus
No relevant data identified.
.3.5.  Mesothelioma*
Asbestos, erionite and painting are IARC group 1 car-
inogens for mesothelioma with sufficient evidence [10].
undreds of studies have investigated the link between
sbestos exposure and mesothelioma [3,59,60]. The first
eries of asbestos-associated pleural mesothelioma cases was
eported in 1960 [61]. The risk for mesothelioma seems to
e higher for some categories of fibers (amphiboles) [2].
.4.  Reproductive  cancers
.4.1.  Mammary  Paget’s  disease  of  the  breast
No relevant data identified.
.4.2.  Epithelial  tumors  of  the  male  breast**
IARC has concluded that shift work involving circadian
isruption is associated with female breast cancer (limited
vidence). Some occupations have been found to be at
ncreased risk for male breast cancer, and exposure to electro-
agnetic fields [EMFs], polycyclic aromatic hydrocarbons,
erbicides, pesticides, and organic solvents have been sug-
ested to increase risk. Nevertheless, most studies focusing
n specific exposures failed to find significant increases in
ssociated risk [62]. However, an increase in risk was asso-
iated with gasoline motor exhaust [63]. More recently, male
reast cancer was suggested to be associated with alkyl phe-
olic compounds that are endocrine disrupting chemicals
64]..4.3.  Epithelial  tumors  of  the  cervix  uteri**
Organic solvents (particularly trichloroethylene) are sug-
ested to be the principal occupational exposure associated
ith cervical cancers [50,65]. Increased risk has also been
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eported for exposure to metalworking fluids [66]. How-
ver, epidemiological studies that reported on this association
id not adjust for well-known risk factors, including HPV.
n addition, histological subtypes have not been well docu-
ented, and results have been inconsistent.
.4.4. Adenocarcinoma  of  the  ovary*
Ovarian cancer is one of the four cancers considered by
he IARC to show sufficient evidence for association with
sbestos exposure [67]. In addition, several other occupa-
ional exposures were shown to significantly increase the risk
or ovarian cancer, including silica dust, diesel exhaust, and
rganic solvents; however, evidence is sparse [68–70]. Also,
eports do not distinguish between histological subtypes of
varian cancer.
.4.5. Epithelial  tumors  of  the  vulva  and  vagina
No relevant data identified.
.5.  Urogenital  cancers
.5.1.  Testicular  cancer**
Several occupational exposures have been suggested to
e associated with TGCT, such as EMF exposure, poly-
hlorinated biphenyls, and pesticides. In addition, several
ccupations have been linked to TGCT, including agricul-
ural workers, firemen, policemen, military personnel, and
ndustrial workers (paper, plastic or metal). However, avail-
ble evidence has not permitted the identification of strong
nd consistent occupational risk factors for TGCT [71]. Since
esticular cancer occurs mainly in young adults, the poten-
ial impact of occupational exposure of mothers to endocrine
isruptors during intra-uterine development has also been
uggested [71,72]. However, data supporting this notion are
parse and inconsistent.
.5.2.  Extragonadal  germ  cell  tumors
No relevant data identified.
.5.3.  Epithelial  tumors  of  the  penis
No relevant data identified.
.5.4.  Squamous  cell  carcinoma  of  the  kidney
IARC has classified trichloroethylene as Group 1 carcino-
en with sufficient evidence for kidney [10]. IARC concluded
hat there is a positive association (limited evidence) with
rsenic and inorganic arsenic compounds, cadmium and cad-
ium compounds, and printing processes [10]. We did not
dentify any studies on this histology sub-type.
.5.5.  Non-transitional  cell  carcinoma  of  the  urinary
ladderIARC has classified numerous occupational exposures
s carcinogens (Group 1) for bladder (no distinction of
istology subtype) with sufficient evidence (aluminum pro-
uction, 4-aminobiphenyl, arsenic and inorganic arsenic
i
i
t
ology/Hematology 90 (2014) 99–134
ompounds, auramine production, benzidine, magenta pro-
uction, 2-naphthylamine, painting, rubber production
ndustry, ortho-toluidine, X-radiation, gamma-radiation) and
imited evidence (4-chloro-ortho-toluidine, coal-tar pitch,
iesel engine exhaust, dry cleaning, occupational exposure
f hairdressers and barbers, printing processes, soot, tex-
ile manufacturing, tetrachloroethylene). Occupational risks
or bladder cancer have been mainly evaluated in regard to
ransitional cell carcinoma; we did not identify any stud-
es investigating occupational exposures in other histology
ubtypes (i.e., adenocarcinoma, squamous cell carcinoma).
.5.6. Non-bladder  urinary  organs  (renal  pelvis,  ureter,
nd urethra)*
IARC has classified aristochloric acids as carcinogenic
or ureter and renal pelvis (sufficient evidence). Occupa-
ional risks for renal pelvis cancer (>90% transitional cell
arcinoma) are those established for bladder cancer [73–75].
ssociations have also been observed with exposure to coke,
oal, asphalt, tar products, and certain refining industries
mineral oil, chemical, and petroleum) [75].
.6.  Neuroectodermic  and  mesodermic  tumors
.6.1.  Malignant  melanoma  of  the  mucosa
No relevant data identified.
.6.2.  Epithelial  tumors  of  the  eye  and  adnexa*
IARC has classified welding with sufficient evidence and
olar radiation with limited evidence for eye.
No occupational exposure study could be identified for
his type of cancer, except for melanoma.
.6.3. Malignant  melanoma  of  the  uvea*
IARC has classified welding with sufficient evidence
nd solar radiation with limited evidence for eye. Occupa-
ional exposure to ultraviolet radiation has been described to
ncrease eye melanoma in workers exposed during outdoor
ccupational activities and welders [76–78].
.6.4. Soft-tissue  sarcoma  (STS)*
IARC classified 2,3,7,8-tetrachlorodibenzopara-dioxin
Group 1) and polychlorophenols and their sodium salts
Group 2B) as carcinogenic for STS (limited evidence). We
id not identify other occupational risk factors for this cancer
ite [79–81].
.6.5.  Bone  sarcoma*
IARC has classified radium (Group 1) with sufficient evi-
ence for association with bone sarcoma. An increased risk
as shown mainly in radium-dial painters [9]. Also, epidemi-
logical evidence supports an increased risk of bone cancer
n plutonium workers [22]. Moreover, epidemiological stud-
es indicated that bone sarcoma is associated with exposure
o medical X- or gamma-radiation. However, large cohorts
n nuclear workers failed to display increased risk for bone
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arcoma, mainly due to small doses of exposure [82]. Fur-
hermore, an increased risk was reported for workers who
ad been exposed to pesticides at work [83].
.6.6. Glial  tumors  of  the  central  nervous  system**
IARC has classified radiofrequency electromagnetic field
including from wireless phones) as carcinogenic for the
rain and central nervous system (Group 2B) [84], but our
eview did not identify data supporting association with occu-
ational EMF exposure. Furthermore, low frequency EMF
xposure has been suggested to increase the risk of glioma,
ut results have been inconsistent [85–88]. Glioma was sug-
ested to be associated with farming activities and exposure
o pesticides, but these findings have not been confirmed
89–93]. In addition, an increased risk of glioma was recently
uggested in workers exposed to carbon tetrachloride [94].
.6.7. Malignant  meningioma**
An increased risk of meningioma in workers exposed
o lead has been described [95–97]. Also, an association
etween meningioma and EMF exposure was reported with
nconsistent results [86–88], and evidence supporting menin-
ioma risk and pesticides is conflicting [91,93].
.7.  Neuroendocrine  tumors
No relevant data identified.
.8.  Endocrine  tumors
.8.1.  Carcinomas  of  the  pituitary  gland
No relevant data identified.
.8.2.  Carcinomas  of  the  thyroid  gland**
According to IARC, there is sufficient evidence that
onizing radiation causes thyroid cancer, but not for occu-
ational exposures (except under conditions of exposure
uring nuclear accidents) [10]. However, some epidemiolog-
cal studies have suggested an excess risk among subjects
ccupationally exposed to ionizing radiation [98–100]. An
ncreased risk of thyroid cancer has also been reported in
omen exposed to organic solvents [101].
.8.3. Carcinomas  of  the  parathyroid  gland
No relevant data identified.
.8.4.  Carcinomas  of  the  adrenal  gland
No relevant data identified.
.9.  Lymphoid  diseases
IARC has concluded that there is a causal relationship
etween lymphoma and several carcinogens with suffi-
ient evidence (rubber industry, 1,3-butadiene) or limited
vidence (benzene, tetrachlorodibenzo-para-dioxin, poly-
hlorinated biphenyls, ethylene oxide, trichloroethylene).
s
F
elogy/Hematology 90 (2014) 99–134 125
elow (Sections 3.9.2–3.9.6), we only report on subtype-
pecific associations.
.9.1. Hodgkin  disease  (HD)**
No strong association has been found with specific occu-
ational exposures. Several studies and meta-analyses have
uggested an association with pesticide exposure [102–104].
lso, studies have indicated an increased risk of HD associ-
ted with wood dust exposure or wood-related occupations
105,106]; however, data are inconsistent and evidence sup-
orting a causal role of occupational wood dust exposure
s lacking according to IARC. Meta-analyses showed no
ncreased risk associated with occupational benzene or other
olvent exposure [107]. Finally, elevated risk for HD, particu-
arly nodular sclerosis, has been reported for subjects exposed
o immunologically active agents [108].
.9.2. Acute  lymphoblastic  leukemia  (ALL)*
According to IARC the relation of ALL and occupational
enzene exposure is supported by limited evidence. The
ssociation is supported by meta-analyses evidence [107].
LL is one of the main radiogenic leukemia subtypes, but
pidemiological data on occupational radiation exposure is
nsufficient. Associations with occupational EMF exposure
as been suggested [109], but evidence is also insufficient.
.9.3. Burkitt  leukemia/lymphoma
No relevant data identified.
.9.4.  Cutaneous  T  cell  lymphoma/mycosis  fungoides**
Studies on occupational exposures that might be associ-
ted with this subtype are rare. However, associations have
een suggested for occupational hydrocarbon and sun expo-
ure [110–112].
.9.5.  Other  T  cell  lymphomas  and  NK  cell  neoplasms**
Studies regarding other T cell lymphomas and occu-
ational exposures are sparse. Data from the European
pilymph study did not support association with solvent
xposure [113].
.9.6.  Diffuse  large  B-cell  lymphoma  (DLCBL)*  and
ollicular B  lymphoma  (FL)*
Occupational benzene exposure was found to be posi-
ively associated with DLBCL and FL in several studies,
lthough the relationship was not significant in all studies
114–118]. Overall, a positive association with solvents has
een reported [113,115,117,119,120], although this appears
o be more consistent for FL than for DLBCL. Also, an associ-
tion of DLBCL with formaldehyde exposure was suggested
117]. For FL, a significant association with combined expo-
ure to benzene, toluene, and xylene has been reported [113].
urthermore, FL has been linked to occupational pesticide
xposure [102,121].
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.9.7.  Hairy  cell  leukemia  (HCL)**
No strong association has been shown with occupational
xposures. A positive association was suggested for farming
102,122,123]. So far, the evidence linking organic solvents
nd exhaust fumes to HCL has been insufficient.
.9.8.  Multiple  myeloma  (MM)*
According to IARC, a positive association of MM with
enzene exposure exists (limited evidence), supported by
pidemiology studies [124–127]. Furthermore, IARC con-
luded that there is a positive association with ethylene
xide exposure (limited evidence). A consistent, but modest,
ncreased risk of multiple myeloma has been suggested for
ccupational pesticides exposure [73,102,128–130]. Resi-
ents and/or workers of sheep farms have shown an increased
isk of MM, indicating that certain animal viruses may be
nvolved. Moreover, a meta-analysis has suggested an associ-
tion with engine exhaust [127]. An inconsistent association
as been shown with chlorinated solvents [113,115,131] and
or work in the rubber industry [126]. Finally, associations
ith occupational exposure to TCDD, formaldehyde, and
adiation have been reported [126,132,133].
.9.9. Other  non-Hodgkin,  mature  B  cell  lymphoma
.9.9.1. Chronic  lymphocytic  leukemia  (CLL)*/small  lym-
hocytic lymphoma  (SLL)**.  IARC concluded that there is
 positive association (limited evidence) with benzene and
thylene oxide exposure [126]. Three meta-analyses have
eported on elevated CLL risk associated with occupational
xposure to benzene, but the findings were not significant
n two of them [107,134,135]. The association with ethyl-
ne oxide exposure is supported by some epidemiological
ndings [136], Moreover, a positive association with other
olvents has been reported for CLL and SLL [113,120,137],
ut overall the results are inconsistent [117,119,135]. Fur-
hermore, an increase in CLL risk has been reported for
ccupational 1,3-butadiene exposure [138]. A positive asso-
iation was identified with occupational exposure to several
lasses of pesticides, but evidence also remains insuffi-
ient for these findings [102,139,140]. Recent studies have
uggested an association with low doses of external ion-
zing radiation, but again the evidence was inconsistent
133,141–143]. Finally, a meta-analysis reported a non-
ignificant increase in risk associated with EMF exposure
109].
.9.9.2.  Marginal  zone  lymphoma/MALT  lymphoma**.
vidence for association of these types of lymphomas with
ccupational exposure is sparse; however, an association with
hlorinated solvents has been suggested [115]. Occupational
nimal exposure has also been linked with ocular adnexal
arginal zone B-cell lymphoma, but the evidence remainsnsufficient [144].
.9.9.3.  Mantle  cell  lymphoma/centrocytic  lymphoma.  No
elevant data identified.
3logy/Hematology 90 (2014) 99–134
.9.9.4.  Lymphoplasmacytic  lymphoma/macroglobulinae-
ia Waldenstrom.  No relevant data identified.
.10.  Acute  myeloid  leukemia  (AML)*
IARC concluded that there is sufficient evidence for a
ausal relationship between AML and benzene exposure
124,126,134]. Moreover, IARC concluded that there is suf-
cient evidence for a causal link between leukemia and
ormaldehyde exposure [126]. Evidence from meta-analyses
upport the associations of AML with both, benzene and
ormaldehyde [124,126,132,134]. Furthermore, a positive
ssociation was found with 1,3-butadiene exposure, with a
ignificant dose–response relationship [126], results not con-
rmed by a recent study [138]. AML is a radiogenic subtype
22], and an increased risk has been shown in a cohort of
S nuclear workers [145]. Meta-analyses have indicated an
ncreased risk associated with occupational exposure to pes-
icides [146]. Furthermore, an increased risk among workers
xposed to diesel exhaust has been suggested [147], but the
ndings are inconsistent. Additionally, some studies have
uggested a positive association with EMF exposure, but
vidence for this remains insufficient [109].
.11.  Myeloproliferative  neoplasms
.11.1.  Chronic  myeloid  leukemia*
The IARC concluded that there was sufficient evidence
o support a causal relationship between formaldehyde expo-
ure and myeloproliferative neoplasms [126]. Evidence from
eta-analyses supports this association [132]. Moreover,
ccording to IARC, there is sufficient evidence that ioniz-
ng radiation causes leukemia. CML is a radiogenic subtype
nd positive associations have been observed [22]. Numerous
pidemiologic studies and meta-analyses have investigated
he association of CML with benzene exposure, reporting
nconsistent results [124,134,135,148,149]. The most recent
eta-analyses provides solid arguments for increasing rela-
ive risks with increasing exposure assessment quality [124].
lso, associations have been suggested for occupational
xposure to pesticides [146]. Data regarding association with
,3-butadiene are inconsistent [138,150].
.11.2. Other  myeloproliferative  and  myelodysplastic
eoplasms**
Although data linking occupational factors to other
yeloproliferative and myelodysplastic neoplasms is sparse,
ssociations with benzene, pesticides, and radiation have
een suggested [135,151,152]..12.  Histiocytic  and  dendritic  cell  neoplasms
No relevant data identified.
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.13.  Childhood  cancer
.13.1.  Childhood  leukemia  (CL)*
IARC concluded that there is a positive association
etween maternal exposure to painting and childhood
eukemia (limited evidence). In numerous case–control stud-
es, a positive association was reported between maternal
xposure to painting (including pre-conception and during
regnancy) and AML (myelocytic, myelogenous, or non-
ymphoblastic leukemia) or ALL (lymphoblastic or lymphoid
eukemia) in offspring [153–157]. In contrast, the association
ith paternal exposure to paints has been inconsistent for
oth ALL and AML [153–155,157–161]. Also, three meta-
nalyses [162–164] have reported an increased risk of CL
ssociated with parental exposure to pesticides; however, the
eukemia subtype, exposure, and periods considered differed
mong the studies. Moreover, an association between CL and
arental exposure to benzene and solvents has been suggested
155,158,159,165–169]. However, evidence on solvent expo-
ure before conception has been inconsistent. While prenatal
xposure to ionizing radiation, mainly through maternal med-
cal exams, has been shown to cause CL [126], studies
egarding maternal or paternal occupational radiation expo-
ure (pre-conception or during pregnancy) and CL risk have
hown inconsistent results [168,170,171]. Furthermore, data
elated to parental occupational EMF exposure have been
nconsistent, and overall suggested a lack of association,
n coherence with IARC monographs [161,168,172–174].
inally, other factors that are suggested to be linked to CL
nclude exposure to motor exhaust fumes, plastic materials,
r woodwork (father). Nevertheless, it is impossible to draw
ny firm conclusions from these data.
.13.2. Lymphoma*
A meta-analysis has suggested increased risk associated
ith parental exposure to pesticides [164]. Also, an increased
isk of non-Hodgkin’s lymphoma was suggested with mater-
al exposure to oil products, unspecified chemicals [168],
nd ionizing radiation [170].
.13.3. Childhood  brain  tumors  (CBT)*
A meta-analysis and two large scale registry-based cohort
tudies found a significantly increased risk of CBT for
aternal [160,164] or parental [175] occupational pesticide
xposure. Moreover, differences according to histologi-
al subtype were found (i.e., a positive association was
eported for astrocytoma, whereas no association was found
ith primitive neuroectodermal tumors [PNET]) [176,177].
aternal pesticide exposure was inconsistently found. Evi-
ence also suggested an association between CBT and
arental occupational exposure to polycyclic aromatic hydro-
arbons (PAH) [178,179], paint [160], and diesel exhaust
180]. Furthermore, some parental occupations were asso-
iated with an increased risk of CBT, including mechanics or
t
s
f
elogy/Hematology 90 (2014) 99–134 127
rivers [181], chemical industry employees [182,183], and
lectrical workers [182].
.13.4. Neuroblastoma**
A meta-analysis suggested increased risk associated with
arental occupational pesticide exposure [164], but the evi-
ence in support of this is insufficient. Data related to other
arental occupational exposures are sparse and inconsistent,
o conclusions cannot be drawn [184,185].
.13.5. Ewing  sarcoma*
Meta-analyses reported a significant increase in risk of
wing sarcoma associated with paternal occupational pes-
icide exposure or farm work [164,186]; however, the data
egarding maternal exposure to these factors were divergent.
vidence related to Ewing sarcoma and other parental occu-
ational exposures is sparse and inconsistent [187].
.13.6. Wilms’  tumor**
Current meta-analyses do not support an association of
ilms’ tumor with parental occupational exposure to pes-
icides [164]. Evidence related to Wilms’ tumor and other
arental occupational exposures is sparse and inconsistent
188].
.13.7.  Other  childhood  cancer**
Parental occupational exposure in other childhood cancers
as been poorly studied. According to IARC a causal relation
sufficient evidence) exists between solid childhood cancer
nd prenatal radiation exposure, in Japanese A-bomb sur-
ivors and through medical exams. However, data on parental
ccupational radiation exposure are insufficient.
. Discussion
Improving prevention and clinical management of rare
ancers are important goals in cancer control. To our knowl-
dge, this is the first comprehensive review on established and
uspected occupational exposures associated with rare can-
ers. The term “rare cancer” recovers a heterogeneous group
f malignancies, i.e., cancers of rare occurrence, rare his-
ology subtypes and rare localizations of common tumors.
lthough the RARECARE rarity threshold (<6/100,000)
ight be considered too high, it has the advantage to be the
ubject of an international consensus [1], and provided a prac-
ical basis for selecting cancers for our review. The common
istologic subtypes of lung and bladder cancer, the malig-
ancies most often linked to occupational etiologies, were
eyond the scope of this review because of their frequencies.
For 40% of the rare cancers included in our review, a posi-
ive association with exposure to occupational carcinogens is
upported by IARC monographs and/or consistent evidence
rom epidemiology studies. However, for many others, the
vidence is lacking or remains sparse and inconsistent.
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The low incidence of rare cancers often constitutes a
arrier to conducting adequately powered epidemiological
tudies. This could partly explain the inconsistent results
eported [111]. Also, in many studies, not designed to inves-
igate histologic subtypes, subtype-specific risk estimates are
ssociated with large 95% confidence intervals and should be
nterpreted with caution [7,41,78,111]. Furthermore, positive
ssociations might be due to chance when multiple test-
ng is performed [189]. Although for some occupations the
ob title can be used as surrogate for occupational exposure
e.g., welders and welding fumes), the reliability of the expo-
ure assessment might be limited for others (e.g., farmers).
lso, heterogeneity of exposure definitions and exposure data
ollected might further explain inconsistencies across stud-
es [190,191]. Furthermore, evolution of industrial practices
ould explain why some previously identified associations
ere not confirmed in more recent studies. Well-conducted
eta-analyses can provide more solid evidence, in particu-
ar when individual studies are inconsistent or insufficiently
owered, such as for parental pesticide exposure and risk
f childhood leukemia [162–164]. This is why our review
onsidered in priority evidence from meta-analyses.
Lack of subtype-specific histopathology details led to the
xclusion of many studies. Also, advances in genetic and
olecular biology have led to improvements in tumor subtyp-
ng (e.g., hematopoietic malignancies and sarcomas) and the
volution of classifications over time [192–194]. For exam-
le, the definition of NHL has evolved over the last decades
nd now includes previously distinct disorders (e.g., CLL,
M), analyzed separately in past epidemiological studies
193,194]. Furthermore, certain genetic polymorphisms of
nzymes involved in xenobiotic metabolism may lead to aug-
ented risk for some individuals [95,195]. However, such
ontributing factors were rarely considered in the reviewed
tudies.
In addition to epidemiology studies, IARC classifica-
ion of human carcinogens takes into account animal and
n vitro studies [196]. Thus, animal studies have confirmed
hat inhalation of asbestos fibers induces lung cancer and
alignant mesothelioma, and several direct and indirect
echanisms have been proposed [197]. Likewise, animal
tudies and mechanistic evidence have shown that the geno-
oxic effects of benzene at the level of the pluripotent
ematopoietic stem cells result in chromosomal changes.
hese are consistent with alterations seen in hematopoietic
alignancies and circulating lymphocytes of benzene-
xposed workers [198,199].
Our study presents several limitations. Given the objec-
ives of our review, after careful review of the evidence
or the 48 cancer sites for which relevant data were iden-
ified, we recorded occupational exposures supported by
ARC classifications, meta-analyses or consistent evidence
rom several epidemiology studies. For selected articles, we
etrieved the most relevant data and provided adjusted risks
hen available. Also, we reported occupational exposures
nconsistently associated with a given cancer site or supported
c
a
c
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y insufficient evidence. However given the wide range of
ancers included in our review, it would have been impos-
ible to record all studies with limited or negative results.
urthermore, the majority of publications in our review were
dentified through PubMed. While we can be confident that
ur combined search strategy enabled us to identify the rele-
ant studies for a given cancer site, we did not perform a cross
earch for occupational exposures identified. Therefore we
annot exclude that some studies focusing on multiple can-
er sites with negative results for a given cancer site, may
ave been ignored.
In conclusion, the main rare cancer sites with strong and
onsistent evidence were nasal, larynx, liver and ovarian
ancer, mesothelioma, bone sarcoma, transitional cell car-
inoma of non-bladder urinary organs and hematopoietic
alignancies. The main exposures for these cancers were
sbestos, wood dust, metals/metalloids, formaldehyde, ben-
ene, vinyl chloride, and radiation. This review provides
seful information to clinicians to pay greater attention to
ork-related exposures in patients with rare cancers. Five
ercent of cancers are of occupational origin [200], but
ccupational cancers remain largely under-reported with
mportant spatial disparities [201,202]. The risk of not seek-
ng compensation is significantly higher for women and the
lderly [203]. Furthermore, care for people with occupa-
ional cancers represents an unnecessary financial burden and
roductivity loss [204]. Due to the latency between expo-
ure and cancer development, work-related cancers often
ppear after retirement, making it important for clinicians
o investigate the former occupations and exposures of
lderly patients. Moreover, patients of the socio-professional
ategories that are most at risk frequently display consider-
ble horizontal occupational mobility, resulting in multiple
ob-related exposures that they might overlook. In many
ountries, patients with certain cancers matching medical
nd exposure conditions can ask for compensation. In the
uropean Union, the recognition of work-related cancers is
ased on a list of registered occupational diseases [205].
lthough several rare cancers (i.e., mesothelioma, sinonasal
ancer) with well-established work-related origins are reg-
stered on various national lists as occupationally related
iseases, these classifications remain heterogeneous among
ountries.
Future research should focus on cancer sites such as NHL
r the upper aerodigestive tract. In this regard, national and
nternational collaborative studies should allow for more
dequately powered epidemiological studies. Moreover, the
ccurate assessment of exposure remains a challenge [191];
herefore, more sophisticated methods for assessing exposure
s well as genetic and molecular biology techniques for eval-
ating gene–environment interactions will be important for
uture epidemiologic research. For instance, we are currently
onducting a case–control study on TGCT to investigate the
ssociation between TGCT risk and life-time exposure using
ombined methodologies, including job exposure matrices,
eographical information system technology, analysis of
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uspected genetic polymorphisms, and socio-economic risk
actors.
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